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ABSTRACT 
Bovine Genital Campylobacteriosis is characterized by early pregnancy loss and temporary 
infertility in cattle. The purpose of this project was to compare diagnostic approaches to detect 
Campylobacter fetus subsp. venerealis and evaluate the efficacy of vaccination for Bovine 
Genital Campylobacteriosis. This thesis describes the results of two studies that compared 
different sample preparation methods for bovine vaginal mucus for real-time PCR and assessed a 
commercial vaccine in preventing infection and reproductive loss.  
The first study compared real-time PCR utilizing different bovine vaginal mucus sample 
preparation techniques to direct culture. The magnetic bead based protocol demonstrated higher 
sensitivity (48.4%, P=0.02) and lower specificity (78.9%, P=0.01) than the heat lysis protocol 
which involved an additional dilution step (Sens=29.4%, Spec=88.2%), but did not differ from 
the heat lysis protocol without sample dilution (Sens=35.0%, P=0.16; Spec=81.1%, P=0.62). The 
sample preparation method, designed for bovine preputial samples (Chaban et al. 2012. Can J of 
Vet Res; 76: 166), did not work well for vaginal mucus. All modifications of that method and 
magnetic bead based extraction technique had low sensitivity compared to culture probably due 
to the biophysical properties of vaginal mucus, which could cause loss of targeted DNA during 
processing, or repeated sample freezing and thawing. Release of DNA directly from vaginal 
mucus by a modified heat lysis protocol with consequent real-time PCR could be a promising 
rapid screening approach after validating on fresh samples. 
The second study compared the risk of infection and reproductive failure in heifers, vaccinated 
with a commercial multivalent vaccine containing C. fetus antigen, to heifers vaccinated with a 
comparable product without C. fetus, that were exposed to infected bulls. There was no 
iii 
 
significant difference between groups either in risk of Campylobacter fetus subsp. venerealis 
isolation (P>0.17) or in the proportion of heifers that cultured positive at least once (P=0.42), as 
well as in the median number times of cultured positive samples (P=0.24) and the time to first 
cultured positive (P=0.67). There was no difference by treatment in the weekly proportions of 
heifers diagnosed pregnant by either ultrasound (P>0.31) or serum concentration of pragnancy 
specific protein B (P>0.31) during the study, as well as in the time to first  pregnancy for heifers 
ever diagnosed as pregnant (P=0.30) and those that remained pregnant at the end of the study 
(P=0.70). Similarly, the difference was not detected by treatment in the proportion of animals, 
ever detected pregnant during the study (P=0.57) and in pregnancy loss rates (P=0.28). However, 
heifers that aborted were 4 times more likely to be cultured positive than those that did not abort 
(P=0.01). Heifers that were not pregnant at the end of the study cultured positive 1.5 times more 
often than pregnant animals in treatment group (P=0.04), while in control group such difference 
was 4 times (P=0.01). Heifers that were not pregnant at the end of the study did not differ by 
treatment in the number of times cultured positive (P=0.14). In this study, the mean 
concentrations of ELISA antibodies to C. fetus after vaccination were more than 2 times higher 
in treatment group than in control group (P<0.02), but vaccination did not significantly reduce 
infection or improve pregnancy in heifers when exposed to Cfv-infected bulls. 
Sample preparation technique is important for successful real-time PCR; release of DNA directly 
from a CVM sample by a modified heat lysis protocol was easy to perform and could be 
promising as a rapid screening approach for Bovine Genital Campylobacteriosis after validating 
on fresh samples. Vaccinating of heifers with a polyvalent commercial vaccine, containing 
Campylobacter fetus antigen, according to the label, did not significantly reduce infection rate or 
improve reproductive performance when they were naturally challenged. 
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1. GENERAL INTRODUCTION AND LITERATURE REVIEW 
1.1. GENERAL INTRODUCTION 
Reproduction is one of the most important factors influencing profitability in the dairy and beef 
industries. Reproductive failure can be due to inability to conceive, pregnancy loss, abnormal 
fetal development and dystocia. Infectious diseases of the reproductive tract are a significant 
cause of reduced reproductive performance. The most common venereal diseases in cattle 
include Bovine Genital Campylobacteriosis and trichomonosis.  
Bovine Genital Campylobacteriosis (BGC) is caused by the bacterium Campylobacter fetus 
subsp. venerealis and characterized by early pregnancy loss and temporary infertility [1, 2]. Bulls 
are carriers and reservoirs for the disease in the herd where bacteria occupy the glandular crypts 
of the prepuce [2, 3]. The infection spreads mainly by coitus, causing inflammation in the female 
genital tract, reproductive failure and large economic loss for the producer [3]. The most 
common diagnostic methods are culture, direct fluorescent antibody test (DFAT), ELISA, PCR.    
The Campylobacter genus contains many species including Campylobacter fetus, which is 
divided into two subspecies: C. fetus subsp. venerealis (previously known as Vibrio fetus subsp. 
venerealis) (Cfv) and C. fetus subsp. fetus (previously known as Vibrio fetus subsp. intestinalis) 
(Cff). These organisms differ in their epidemiology and clinical importance; therefore, accurate 
differentiation is essential, but can be quite difficult if based on traditional biochemical analysis 
[4–7]. For instance, C. fetus subsp. venerealis biovar intermedius (Cfvi) can cause BGC, but 
possesses biochemical features of Cff [8].  
Molecular diagnostic methods have been considered to be the most promising for C. fetus sub-
speciation [9, 10]. Genome size is very similar in both subspecies; however, the genome of most 
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Cfv strains is about 228 kbp larger than Cff [9] and several genes are subspecies-specific [10]. 
Conventional PCR, targeting the gene encoding carbon starvation protein A (CstA) (present in 
both subspecies) and the parA gene (present only in Cfv), correlates well with other typing 
methods when performed directly on colonies from culture media [11, 12].  
Successful cultures are influenced by sampling, sample transport conditions, media and 
environment; therefore, molecular diagnostics may be more robust for direct evaluation of field 
samples. The correct sample preparation technique is important for a successful PCR assay. A 
real-time PCR assay has been successfully utilized for testing bull preputial samples [13], but the 
sample preparation method needs to be validated on bovine vaginal mucus.   
Cfv causes endometritis and innate immunity is a vital protection mechanism for exposed female 
cattle. Inflammatory mediators typically include the interleukin cytokines, tissues necrosis factor, 
chemokines, interferons and prostaglandins [14]. Acquired immune response includes humoral 
and cytotoxic immunity. Mucus membranes of the uterus are characterized by a greater IgG than 
IgA response, depending on the stage of the estrous cycle [15].  
Vaccine-induced immunity is usually effective but short-lived and an annual booster is required 
[16]. The efficacy of vaccines depends on the antigens and adjuvants they contain [17]. 
Unfortunately, vaccines are not commonly used in the herds most at risk of BGC and there is a 
relatively small number of peer reviewed publications regarding vaccination for this infection. 
There is a need to be a better understanding of the efficacy of vaccination in order to make better 
decisions for a herd’s protection.   
This review will focus on the etiology, epidemiology, pathogenesis, diagnosis and control of 
BGC in female cattle.     
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1.2.  ETIOLOGY AND DISTRIBUTION OF BOVINE GENITAL 
CAMPYLOBACTERIOSIS   
Cfv is the etiologic agent for BGC. Campylobacter belongs to class Epsilonproteobacteria and 
the bacteria of this class are highly adapted to mucosal surfaces. These are spiral shaped, slender, 
curved rods with a corkscrew type of motility due to a polar flagellum on one or both ends, 
usually 0.2-0.3 x 1.5-5 µm in size, but can be up to 8 µm long [5, 18]. A microaerophilic 
environment is essential for survival of C. fetus; energy for metabolism is obtained from amino 
acids and intermediates from the tricarboxylic acid cycle [4]. The pathogen is a slow growing, 
oxidase and catalase positive. Differentiation between C. fetus subspecies has been based on the 
ability of Cff to grow in the presence of 1% glycine and produce H2S the medium supplemented 
with 0.02% cycteine-HCl. Cfv do not possess such properties. However, intermediate strains 
Cfvi have been shown to produce H2S [8], tolerate 1% glycine [9, 19], and cause BGC [20].    
BGC is responsible for fetal losses in cattle and often undetected until pregnancy examination. A 
high number of animals, exhibiting estrus after the breeding season, could be a diagnostic clue. 
The economic impact can be severe. For instance, an outbreak in Saskatchewan led to a 70% 
pregnancy rate in one group and a 24% rate in another group of heifers, bred to different infected 
bulls [21]. When compared to pregnancy rates of 86, 87 and 88% in three other groups of heifers 
bred to different uninfected bulls, a 16–62% reduction in pregnancy rates was reported [21].     
BGC is distributed worldwide, although there is a lack of reliable data from many countries [3]. 
The disease has been diagnosed in Europe [22, 23], Asia [24, 25], Africa [26–28], North 
America [2, 21], South America [29–31], Australia and New Zealand [32–34]. BGC is common 
in developing countries, where natural breeding is practiced in both dairy and beef herds, while 
in developed countries it is usually limited to beef herds [35].  
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C. fetus has been found worldwide in cattle (Table 1.1.), and the reported prevalence varied from 
0% to 53% [2, 26, 37, 25–29, 37–46]. The reported prevalence of Cfv was from 0.9% [26] to 
17.2% [37] in general, in bovine preputial samples it was 1.8–17.2% [26, 28, 37–40], and in 
bovine vaginal mucus it was 0.9–3.1% [26, 28]. The prevalence of Cfvi in preputial samples was 
reported as 12.3% in Nigeria [38] and 17.2% in South Africa [37].  
 1.3. PATHOGENESIS IN COWS AND HEIFERS  
1.3.1. Maintenance of Campylobacter fetus venerealis  in the bovine female genital tract  
While infection results in an asymptomatic carrier state in bulls [47, 48], cows and heifers 
experience transient infertility [49], associated with inflammation in the reproductive tract [50]. 
The ability of Cfv to persist in the presence of the host immune response is not fully understood. 
However, antigenic variation is suggested as a possible mechanism and has been observed in 
both subspecies of C. fetus [51–53].  
Many changes happen in the antigens expressed on the bacterial surface during infection. In one 
study, Cfv was isolated from a human and inoculated into the uterus of a BGC-negative heifer. 
Isolates obtained from vaginal mucus on a weekly basis exhibited variations in high molecular 
mass protein profiles when compared to the original inoculum [54]. In another study, Cfv, 
isolated from a bull twice in a 49-day interval, showed different patterns of surface array proteins 
[55]. Marked antigenic variation was demonstrated in monthly isolates from the two heifers by 
agglutination tests. Changes in antibody specificity in cervico-vaginal mucus (CVM) and 
antigenic variation in the bacteria were proposed as a possible mechanism for prolonged 
maintenance of Cfv in the reproductive tract in the presence of mucosal antibody, leading to an 
asymptomatic cervico-vaginal carrier state [53].  
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1.3.2. Immunity against Campylobacter fetus  
Protection against pathogenic invaders begins with physical barriers. The vulva, vagina and 
cervix protect the uterus from ascending infection. Other physical barriers include the epithelium 
of the vagina and endometrium, basement membranes of ovarian follicles and the zona pellucida 
of oocytes [14]. Antimicrobial peptides and glycoproteins cover the mucosa to prevent bacteria 
from reaching the endothelium and neutralize the invader [56].         
Cervical mucus is produced by mucus-secreting epithelial cells in the cervix. The mucus 
comprises two phases: aqueous and gel [57]. The aqueous phase contains low molecular mass 
compounds that are dissolved in up to 95% water [58]; the gel phase is formed mainly by mucins 
[57, 59]. Properties of CVM are controlled by estrogen  level [57]. Mucus is secreted during the 
whole cycle, but its volume increases at estrus under estrogenic influence. CVM is a good 
substrate for Cfv growth, but it also contains immune cells and immunoglobins [60].  
Innate immunity is vital to protect the female reproductive tract from microbial infections. Toll-
like receptors (TLR) and Nod-like receptors (NLR) are pattern recognition features on host cells 
that are able to sense pathogens [14]. The TLRs and NLRs bind pathogen-associated molecular 
patterns (PAMP), found exclusively in prokaryotes [61]. In addition, some substances, such as 
nucleic acids, ATP and IL1α, released from damaged or dead cells and known as damage 
associated molecular patterns (DAMP), are believed to bind pattern recognition receptors as well 
[reviewed in 14].  
There are several kinds of TLRs and NRLs that localize in the different parts of host cells 
binding different PAMPs. The most important TLRs are TLR1, TLR2, TLR6, functioning to 
bind microbial lipopeptides, and also TLR4. TLR4 principally binds the cell wall component of 
6 
 
Gram-negative bacteria, such as Campylobacter, at the lipopolysaccharide (LPS, endotoxin) [14, 
61, 62] and responds by secreting inflammatory mediators, such as cytokine IL6, chemokine IL8 
and prostaglandin E2. Activation of other TLRs leads to production of other mediators of 
inflammation, such as interferons. NLRs, such as NOD1, NOD2, NLRP3 and NLRC4, are intra-
cytoplasmic receptors of host cells that able to differentiate exogenous molecules from microbial 
molecules, which is important in case of intracellular pathogens, not Cfv. NLR activation leads 
to cleavage of caspase-1 to an active form and production of mature cytokine IL1β, which is 
another inflammatory mediator [14, 62]. Inflammatory mediators recruit neutrophils and 
monocytes to the site of infection [61].    
Since many pathogens have evolved strategies to avoid host defenses, adaptive immunity is 
important. Antibodies are especially important in the defense against extracellular pathogens. It 
has been hypothesized that IgA acts to immobilize Cfv while the action of IgG is opsonization 
[63, 64]. Both serum and CVM from virgin heifers, systemically immunized with Cfv bacterin, 
opsonized Cfv organisms of the same strains as were in bacterin preparation. However, CVM 
from the animals, locally immunized with the same bacterin, was not opsonic [63]. This 
suggested that local vaccination most likely did not stimulate release of IgG. In another study, 
immunoglobulins classes A and G were proven to be essentially equally protective against 
Trichomonas foetus [64]. The same could be true for Cfv, since both organisms cause diseases 
that are similar in their epidemiology and pathogenesis; however, more research is warranted.   
BGC does not significantly induce systemic antibodies during or after infection [48, 65]. Unlike 
bulls, bovine females develop local antibody responses in the vagina and uterus. Heifers, 
challenged with Cfv, had agglutinating and immobilizing transient IgM antibodies, followed by 
persistent IgA and IgG antibodies in vaginal secretions, with predominantly IgG antibodies in 
7 
 
uterine secretions [64]. Since CVM from the locally immunized heifers did not demonstrate 
opsonic activity in one study [63], it could be suggested that IgA is predominant in vaginal 
mucosa. Because there is a more robust antibody response in female genital mucosal secretions, 
Cfv infection is not as persistent in cows as it is in bulls [66–68].  
In general, genital IgA are of longer duration than IgG. IgA lasted at least 10 weeks after vaginal 
vaccination, preventing re-colonization of the uterus in vaginal carriers, immobilizing Cfv; 
however, the pathogen persists in cervico-vaginal area since opsonization does not occur [63, 
64]. The local vaccination against BGC, performed by intra-vaginal-cervical route, most likely 
elicits increase of IgA in CVM and subsequently prevents colonization of uterine cavity [63]. 
Systemic vaccination leads to higher level of systemic IgG that consequently are secreted mostly 
to uterine and in some degree into vagina [64].  
Whether evasion of host response or protection is predominant probably depends on the 
magnitude, specificity and isotype of the immune response, as well as the evasive capabilities of 
the microbes. Since Cfv is an extracellular pathogen, it is expected that mainly antibody 
responses are associated with protection. Cell-mediated immunity is also likely to play some 
role, particularly in vaginal cariers or later in infection where lymphocytes are numerous [52]. 
Both T-cells and antigen processing cells have been shown to be present in the mucosa; 
phagocytosis, following opsonization with specific antibodies, effectively killed Cfv [48].  
1.3.3. Infertility and pregnancy loss associated with Bovine Genital Campylobacteriosis 
Infection with Cfv in bovine females can result in reproductive failure [65, 67–73]. In one older 
study, 10 days after inoculation Cfv localized in the cervix and vagina and resulted in infertility 
lasting up to 10 months [71]. In another report, the average conception rate was 40% for the first 
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service in 106 previously unbred heifers, served by infected bulls; 57% developed BGC and only 
21% of these became pregnant, whereas among those that escaped infection the conception rate 
was 67% [74]. Artificially infected heifers conceived with an average 72-day delay after first 
service and exposure, compare to 13 days in uninfected animals [75].  
The inoculation of viable Cfv into the uterus of cows in the second trimester of pregnancy 
resulted in abortion in 5–7 days; fetal death happened several days before expulsion, and the 
level of progesterone in peripheral plasma declined at the time of fetal death. Cows, inoculated 
during the third trimester, aborted in an average of 13 days and decline of progesterone levels on 
the day of abortion was similar to that in normal parturition [76]. Similar results were obtained 
after inoculation into the placental cavities [77]. Decline of progesterone at the time of abortion 
might be due to placental dysfunction and luteolysis, likely because of the products released 
from autolysis of the infected fetus [76]. The possibility that Cfv directly acts as a luteolytic 
factor seems questionable as Cfv prolonged the functional life of the corpus luteum (CL) in 
sheep in another study [78]. 
Cfv was located by immunofluorescent technique within the endometrium of experimentally 
infected heifers and recovered from the lungs, abomasum, and occasionally from the liver, 
spleen, and brain of aborted fetuses [77]. The most frequent fetal lesions from artificially induced 
BGC were neutrophilic bronchopneumonia and interstitial pneumonia [79]. When aborted 
between 129 and 187 days of gestation, fetuses were partially macerated but did not show 
remarkable lesions, suggesting inability to develop the adequate immune response [77]. Fetuses 
aborted after 222 days of gestation demonstrated grossly fibrinous peritonitis, pleuritis and 
hepatitis, accompanied by necrotizing placentitis [77, 79]. Histologic observations included 
changes of a proliferative nature such as reticuloendothelial hyperplasia and plasma cell 
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infiltrates in the lamina propria of the tubular organs [77]. Therefore, fetuses, infected in later 
gestation, resisted to a greater degree, since they developed a greater immune response that can 
be assumed based on the more prominent gross lesions [77–79].   
It has been suggested that Cfv causes infertility in cows by restricting the supply of oxygen to the 
pre-implantation embryo [80]. However, the effect of Cfv on embryonic development has only 
been studied in murine embryos [81]. Differentiation and hatching percentages were evaluated 
from morulae, while hatching, adhesion and expansion percentages were noted from blastocysts, 
cultured with the addition of C. fetus. There was no negative effect on the early embryonic 
development, but the differentiation percentages were 16% less and hatching percentages were 
22% more than in morulae and blastocysts, cultured without C. fetus [81]. 
1.4. DIAGNOSIS 
1.4.1. Samples  
Sample characteristics 
Blood, preputial material, CVM, aborted fetuses and placenta can be used for BGC testing. 
Serum and CVM are used for immune-based diagnostic methods, while other samples are used 
for pathogen detection and/or isolation. Preputial samples can be a mixture of different 
components, such as smegma, blood, epithelial cells, urine and feces, but they are usually not as 
viscous as CVM. Properties of CVM, unlike preputial samples, depend on the stage of the 
reproductive cycle when sampling was done [82]. Normal microbiota together with possible 
contaminants from feces make preputial samples complex to investigate [83, 84], while CVM is 
usually less contaminated with environmental microorganisms, compared to preputial samples. 
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However, CVM is also contaminated and the goal of good sampling to reduce the contamination 
as much as possible [82]. 
Bovine CVM comprises aqueous and gel phases [57]. The aqueous phase contains soluble low 
molecular weight non-organic compounds while gel phase contains insoluble high molecular 
weight organic compounds [57, 59]. Biophysical and chemical properties of CVM may pose a 
challenge for some diagnostic techniques to perform.  
There is an inverse relationship between the dry matter content in the aqueous phase and the 
degree of crystallization [60]. Decreasing in proportion of salts such as NaCl, KCl and CaCl2 in 
the aqueous part of CVM leads to decreasing water content. Such changes cause a decrease in 
crystallization and a relative increase in other salt components in the dry residue [85, 86]. The gel 
phase of CVM is responsible for reological properties of vaginal mucus [59].  
Dry matter concentration and crystallization patterns of bovine CVM, as well as its visciosity 
vary during the estrous cycle and early pregnancy [57, 85]. Dry matter concentration reached a 
minimum value on the day of estrus and a maximum value at the mid-cycle [85], while 
crystallization increased on the day of estrus [82, 85, 86]. Dry matter concentration of CVM 
increased from the day of estrus to the 19th day of gestation, while crystallization decreased 
during this period [85]. During the pre-ovulatory period of estrus cycle CVM is less viscous and 
more hydrated, making easier posterior movement of spermatozoa [57]. In the luteal phase the 
viscosity increases preventing migration of sperms [59].  
Therefore, whenever CVM is collected it appears “gelly” due to either high viscosity or 
crystallization. Such appearance could cause DNA loss with pellet when samples are prepared 
for real-time PCR [57, 59, 82, 85, 86].   
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Sample collection and transport 
Aspiration, washing and swabbing of the vaginal cavity can be used to obtain CVM [3]. To the 
author’s knowledge, there are no data comparing aspiration and washing methods for vaginal 
mucus sampling.  
For aspiration, an artificial insemination (AI) pipette, attached to a syringe, is inserted into the 
vaginal cavity so that the anterior end of the pipette reaches the cervix; suction is applied while 
moving the pipette gently backwards and forwards [3]. For washing technique, 20–30 ml of PBS 
is infused into the vagina through an AI pipette, attached to a syringe; the fluid is sucked out and 
re-infused several times before being collected. Washing fluid may also be collected from the 
vaginal cavity by inserting and holding a tampon or gauze after PBS infusion inside of the vagina 
for 5–10 minutes. Obtained samples may be diluted with PBS or placed directly onto transport 
and enrichment media (TEM) for culture [3].   
Under field conditions samples are often in transportation to lab for >24 hours. C. fetus is very 
sensitive to temperature conditions. In some Canadian provinces, such as Saskatchewan, high 
temperatures in summer and extremely low in winter make sample delivery quite challenging. 
Cfv is a microaerophilic pathogen that requires minimal oxygen for survival; therefore, transport 
media should provide such conditions.  
When culture is used as a diagnostic method it is essential that samples arrive in a laboratory 
within 6–8 hours of collection [87, 88]. The poor survival of the organism during transport leads 
to false negative results [6, 44]. Transport media can help to maintain viability, enhance 
multiplication of Campylobacter, and prevent contaminant overgrowth [88]. Several TEM have 
been described in literature and summarized in Table 1.2.  
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1.4.2. Culture 
Isolation by culture is the most common BGC diagnostic method and considered to be a gold 
standard test [3]. Poor viability of Cfv is one of biggest obstacles in culture-based testing, 
leading to specific requirements for culture medium and techniques. The bacteria need 85% 
nitrogen, 10% carbon dioxide and 5% oxygen in the atmosphere to survive and replicate [47]. To 
prevent other bacterial overgrowth while supporting growth of Campylobacter, filtration and/or 
selective agar must be implemented.  
The filtration of samples with a filter of 0.65 µm pore size prior culturing has been recommended 
to improve isolation rate of Cfv [89, 90]. Historically it was performed with positive pressure on 
the sample [91], but this resulted in obstruction of the filter pores with tissue particles, 
consequently reducing colony counts by up to 90% [92]. The filtration method has been 
improved by using passive filtration that allows motile Campylobacter to migrate through the 
filter pores, resulting in 87% sensitivity when Skirrow’s agar was used [93].  
Selective media are agar-based with inclusion of 5–10% blood and specific combinations of 
antibiotics [57, 91]; the most common are campylobacter-selective agar (CSA) and Skirrow’s 
agar [94]. CSA contains antibiotics polymixin B, bacitracin, cycloheximide, novobiocin and 
demonstrated sensitivity of up to 94% when samples were plated within 2–4 hours after 
collection [88, 92, 94, 95].  Skirrow’s agar, containing higher concentrations of polymixin B than 
CSA agar plus vancomycin and trimethoprim, can be used for isolation of thermophilic 
Campylobacter [96] with up to 68% of sensitivity [88, 94]. CSA demonstrated higher sensitivity 
than Skirrow’s agar possibly due to susceptibility of some Cfv strains to polymixin B [94]. 
Contamination of samples with fungi reduces the available surface for other organisms in the 
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medium, and cycloheximide in CSA appears to control this, while Skirrow’s agar does not 
contain antifungal agents. However, the addition of amphotericin B and use of passive filtration 
can control fungal growth [90, 93].  
C. fetus are generally catalase positive, do not produce H2S in media, negative for hippurate 
hydrolysis, sensitive to cephalothin, do not grow in the presence of a hypertonic solution (such as 
3.5% NaCl) and cannot tolerate a temperature above 42
0
C [97]. For subspecies differentiation, 
the gold standard method has been the culture in the presence of 1% glycine since Cfv is glycine 
sensitive and Cff is glycine tolerant [3, 90]. However, glycine tolerance can be acquired through 
mutation or transduction [98], and glycine sensitive strains of Cff have been reported [99]. Cff, 
unlike Cfv, has been known to produce H2S [3, 90]. However, Cfvi has the ability to produce 
H2S [7, 8] and some isolates tolerate 1% glycine [9, 19], which would give false negative results 
for BGC in the glycine tolerance test. In addition, phenotypic characterization of Cfv can be 
influenced by the inoculum size and basal media, resulting in poor reproducibility [12, 100].  
The combination of filtration and selective agar has been suggested as a highly sensitive 
technique in spite of possible disadvantages [91]. While there is no ideal single method for 
identifying Cfv, the best strategy is to combine synergistic approaches [6, 101].          
1.4.3. Immune-based methods 
Both direct and indirect immunological assays exist for the detection of C. fetus. Direct 
fluorescent antibody test (DFAT) and capture enzyme-linked immunosorbent assay (ELISA) are 
examples of the direct tests, while MAT and ELISA are examples of indirect assays.  
DFAT detects C. fetus antigen, labeled with fluorescein isothiocyanate (FITC) [102, 103], and 
results can be obtained in a couple of hours [43]. However, if a large number of samples need to 
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be processed, this test is laborious and demands a certain level of expertise to perform. When 
compared to culture, DFAT had similar or greater sensitivity [43, 102, 103], ranging from 80% 
to 94% [88, 92, 104], and specificity has been estimated as 89% [43, 104]. In situations where 
CVM could not be cultured within 6 hours after collection, the DFAT appeared to be more 
sensitive method than culture [105]. DFAT has not been able to identify subspecies [43, 88, 92, 
102–105]. 
Recently a monoclonal antibody (MAb) capture ELISA was developed and utilized on preputial 
samples, where four monoclonal IgG antibodies were used against epitopes in the LPS O-
antigens of C. fetus serotype A and B strains [106]. However, the assay could not differentiate 
Cfv form Cff since both shared the same serotype A [106, 107]. In the different study, systemic 
vaccination did not interfere with the IgA ELISA on vaginal mucus samples in cows because 
only IgG were present in vaginal mucus. Due to possible false reactions, caused by antibody 
fluctuations in individual cattle, the ELISA is best as a herd test [108]. Repeated collection of 
CVM samples provoked suspicious and false positive reactions in the cervicovaginal mucus 
agglutination (CMA) test, likely because minor sample collection trauma caused an increase in 
plasma-derived agglutinins in the vagina [109].  
The ELISA method was adequate for the evaluation of the systemic immune response in 
vaccinated bulls [110]. Utilizing of the common indirect immunoassays (MAT and ELISA) in 
cows and heifers could be problematic due to low sensitivity of agglutination assays and 
subjective results interpretation. Antigen preparation method also matters. Detergent soluble C. 
fetus antigens have shown better results than other antigen preparations in ELISA [111]. In 
another study, where acid glycine extract (AGE) and whole cell (WC) antibodies were used in 
ELISA for the detection of Cfv and Cff antibodies in bovine blood sera, AGE antibodies were 
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more specific than WC antibodies. A cross reaction was detected between subspecies which led 
the authors to conclude that ELISA could only be useful as a monitoring test [112].             
1.4.4.  Molecular diagnostic techniques 
Molecular diagnostic techniques for BGC are attractive because they are fast and do not require 
viable Cfv in the sample [9, 11, 113–137]. In addition, molecular methods have been shown in 
several studies to differentiate Cfv and Cff [9, 11, 99, 113, 114, 116, 118–122, 126, 129].  
Described polymerase chain reaction (PCR) assays to detect Campylobacter fetus venerealis  
Several PCR methods have been developed to differentiate C. fetus from other Campylobacter 
species or other bacteria. Many PCR assays targeted the ribosomal RNA operon or the cpn60 
gene [113–117]. In addition to its usefulness at the species level, 16S rRNA gene-based PCR 
was subsequently included in studies for Cfv detection [113, 114, 116]. Numerical analysis of 
pulse field gel electrophoresis DNA (PFGE-DNA) profiles was claimed as an effective method 
for differentiating C. fetus subspecies [117]. PFGE could also differentiate subspecies of C. fetus 
based on estimated genome size [9].  
A multiplex PCR assay, described by Hum et al. in 1997, has been used worldwide for detection 
and subspecies discrimination of C. fetus. The assay utilizes two pairs of primers: MG3F/MG4R, 
targeting the carbon starvation protein A gene (cstA), common to both subspecies, and 
VenSF/VenSR targeting the parA gene, considered to be exclusively present in Cfv [11].  
Agreement with the glycine tolerance test was reported to be 70–100% [117–122].  
The VenSF / VenSR primer set has been validated through 15–20 years of testing and considered 
reliable in the face of new discoveries [13]. However, two Campylobacter hyointestinalis isolates 
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produced false positive results with a Cfv specific assay in one study because parA or a close 
homologue was present in C. hyointestinalis isolates [123]. According to recent evidence parA 
gene, located on a transferable genomic island [18], could be potentially spread among 
Campylobacter species. Significant discrepancies were reported between Hum primer-based 
PCR and phenotypic methods on 17 Cfv isolates in the UK [124] and 40 Cfvi isolates from 
South Africa [122]. These disagreements might be due to Hum PCR failure or differences in 
phenotypic test conditions [120, 125]. Therefore, the positive results should be confirmed by 
additional tests and more research is warranted.    
Other PCR tests, targeting the parA gene, have been reported, including a 5' Taq nuclease assay 
[126] and another, in which Hum's Cfv specific primers were adapted to the SYBR Green qPCR 
platform [13]. These tests employed samples, prepared by heat lysis of direct preputial samples 
rather than a DNA isolation method, had a detection limit of just a one bacterial cell equivalent 
per reaction [13], and both were more sensitive in field trials than Hum primers-based 
conventional multiplex PCR [13] and culture [126]. The interesting feature of qPCR tests is the 
possibility of Cfv quantification in the sample; however, the lack of standardization remains an 
issue [13, 84]. 
ISCfe1 is an insertion element in the Cfv genome. To target ISCfe1 a set of primers has been 
developed: CVEN-L and CVEN-R2, and PCR results agreed 100% with glycine tolerance testing 
and 98% with Hum primers based PCR [121]. Yamazaki et al. (2010) developed a loop mediated 
isothermal amplification (LAMP) assay using the ISCfe1 targeting primers that had 100% 
agreement with phenotypic profiling in C. fetus subspecies differentiation [127]. More recently, 
TaqMan real-time PCR, based on targeting of ISCfe1, has been developed for Cfv detection 
[128]. So called primers CampF4/CampR4, targeting ISCe1 in a SYBR Green based assay, 
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demonstrated better subspeciation of C. fetus than VenSF/VenSR primers on 1071 isolates with 
sensitivity of 98.7% and specificity of 99.8% [129]. All of these studies have been performed on 
isolates and there are no data found about direct use of these types of tests on field samples.       
Van der Graaf-van Bloois et al. (2013) concluded that none of the published PCR assays were 
able to identify C. fetus strains correctly at a subspecies level [130]. The C. fetus species 
identification demonstrated 100% sensitivity and 100% specificity. Development of subspecies-
specific real-time PCR, targeting ISCfe1, failed due to variation of the target insertion sequence 
and prevalence in other Campylobacter species. One of possible reasons could be the presence of 
inhibitors in the PCR products [130].  
A whole genome comparison between Cfv and Cff has been possible since the complete genome 
sequence of the Cfv type strain (ATCC 19438
T
) was determined [131, 132]. Three pathogenicity 
islands were identified in Cfv, based on the comparison to the Cff strain 82-40 [10]. One of these 
contained the parA gene and several other genes involved in a type IV secretion system (T4SS).  
T4SS is thought to play a role in protein transmission to host cells [13, 18]. Some of these genes 
have been previously used as targets for PCR primers. For example, VirB11 gene was used as a 
target in an assay developed by Moolhuijzen et al. in 2009 [133]. Later, Iraola et al. (2012) 
successfully utilized these [133] and Hum’s [11] primers in their multiplex PCR assay to analyze 
the abomasal liquid of aborted bovine fetuses without performing pre-enrichment steps [134].   
Sample preparation methods for PCR 
In molecular diagnostics, sample type and preparation techniques play a significant role in the 
success of the test. In one study, better efficiency of PCR was obtained from fetal abomasal 
fluids than from lung tissues [79]. Groff et al. (2010) evaluated PCR on bull prepuce samples, 
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cow CVM, and abomasum contents of aborted fetuses, prepared with five lysis protocols: 
thermal, proteinase K, with guanidine isothiocyanate, with DNAzol and with 
hexadecyltrimethylammonium bromide (CTAB). The CTAB protocol provided the best results: 
24% of 277 clinical samples were positive for C. fetus using PCR, while only 2.8% were positive 
by culture [135].  
Blood, being a common component of most TEM, can inhibit PCR [136]. In order to combat 
possible inhibitory effects, multiple-step DNA isolation protocols, such as those based on 
magnetic beads, have been developed and shown to be effective for preparation of clinical 
samples for PCR testing [137]. This method offers potential advantages for PCR-based 
diagnostic testing for BGC where the gel consistence of vaginal mucus presents a particular 
challenge.     
1.5. CONTROL AND PREVENTION 
1.5.1. Control strategies 
The best method of BGC prevention is utilizing AI instead of natural breeding; however, the 
fresh semen must be from Cfv-free bulls. AI is more commonly used in dairy than in beef herds. 
Segregation of potentially infected and uninfected animals in combination with extensive culling 
practice can also control BGC, but requires meticulous records and biosecurity [138].  
Repeated sampling increased the probability of detecting infection: 2–6 repeated samples tested 
negative usually provided conclusive evidence of true Cfv-free status [31, 95, 139]. One study 
reported an increase of culture sensitivity form 39% to 95% when 3 repeated samplings were 
performed [47]. Combining culture and conventional PCR enhanced Cfv detection in bulls, as 
well as parallel use of DFAT and culture, or using selective media and filtration [140].  
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In female cattle, convalescent immunity is partially protective. Cows, re-infected within two 
years of clearing the infection, were protected against reproductive failure but became vaginal 
carriers; therefore, enhancement of immunity might result in total clearance of infection [141].  
Treatment and prevention might help either eliminate disease from the herd or control it at the 
minimal acceptable level. In one study, 75% of preputial samples were cultured negative after 30 
days of treatment with a 20% solution of dimetridazole chlorhydrate, 14.3% were negative after 
fluoquinolone treatment and 100% after long action oxytetracycline [142]. However, it is 
unknown whether subsequent samplings were performed after the end of the trial to be sure that 
bulls remained negative. Cows are not usually treated for BGC for practical reasons and 
vaccination has been remained as the main preventive method.  
Systemic immunization has been believed to prevent or eliminate Cfv infection by inducing IgG 
antibodies in genital secretions and serum, shortening infection and reducing reproductive losses 
[48, 143]. Active or passive immunization with Cfv could cure a vaginal carrier state in one 
study [144]. The mechanism of IgG1 transport across the epithelium is not well understood. A 
lack of IgE might be partially responsible for the delay in appearance of IgG1 in genital 
secretions [141]. The IgE response depends upon transport of IgG1 to peripheral organs [141].   
Convalescent immunity is associated with the mucosal IgA antibodies, transported across the 
epithelium via the Poly-Ig receptor, and is partially protective. Systemic immunization is thought 
to clear the chronic infection early enough to prevent adverse outcomes for pregnancy [141]. 
However, neither vaccinated nor control heifers had a significant increase of systemic antibodies 
in one study, having only a slight increase after the breeding, most likely due to natural stimulus 
by the infected bull [145].  
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1.5.2. Vaccination for Bovine Genital Campylobacteriosis  
Vaccines that have been used and questions of their efficacy 
Vaccination for BGC has been considered as a safe and highly effective treatment and preventive 
measure [17, 41, 68, 146–151, 153–157]. Relatively few peer-reviwed studies have been 
performed in order to assess effectiveness of monovalent and polyvalent, commercial and 
experimental vaccines for bulls [17, 152–154, 156–158] and cows or heifers [68, 145–153, 155, 
157]. The methods of vaccination, challenge, results and authors conclusions are summarized in 
Table 1.3.  
Vaccination with monovalent vaccine has been reported in 1960–80-ties as effective method  
[17, 41, 68, 146–149, 151, 153–157]. In one study, the calving rate of vaccinated beef cows, 
mated with infected bulls, was 82%, compare to 59% for unvaccinated cows and 84% for cows 
mated with uninfected bulls [146]. Conversely, the proportion of either calved late or non-
pregnant was 18% in vaccinated and 41% in unvaccinated cows [146]. In another study, vaccine, 
prepared from an Australian isolate of Cfvi was injected into 23 virgin Guernsey heifers while 10 
unvaccinated animals served as controls [147]. When challenged intravaginally with Cfvi 
culture, weekly vaginal swabs demonstrated the infection in 80% of unvaccinated animals, 
compare to 13% of vaccinated animals [147]. Vaccination of 188 bulls with monovalent vaccine, 
prepared with local antigen in incomplete Freund’s adjuvant, resulted in their non-infected status 
after natural exposure in infected areas for 1 year [41]. In another trial, vaccination of 46 heifers 
and 4 bulls with monovalent vaccine, prepared with local strain, resulted in 33% of infection rate 
in vaccinated heifers, compare to 68% in control group, and none of 4 bulls were infected [157].   
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The effectiveness of polyvalent vaccines is questionable. In one study, commercial vaccine, 
formulated with inactivated antigens of Leptospira interrogans serovar pomona, Haemophilus 
somnus, Cfv and Cff, viruses of the infectious bovine rinotracheitis and bovine viral diarrhoea in 
aluminium hydroxide adjuvant, was used to vaccinate heifers that were naturally challenged for 
60 days [145]. Vaccinated and control heifers had a poor reproductive performance and did not 
increment of systemic antibody level [145].  
Commercial and experimental dual vaccines, containing Tritrichomonas foetus and C. fetus 
antigens, were compared to controls. Vaccinated heifers resisted or quickly cleared both 
pathogens, had a higher pregnancy rate, and a better immune response [150]. The experimental 
vaccine, containing antigens from local strains of C. fetus and T. foetus, given both subcutaneous 
(SQ) and intravaginal, was superior to the commercial vaccine [150]. Whether that was due to 
the fact of using local strains of pathogens when the experimental vaccine was prepared or due to 
local application of the preparation, remained questionable.    
Antigenic difference between local strains and changes in pathogenicity during infection may 
reduce vaccine effectiveness [68]. This phenomenon was illustrated in one study in which a 
commercial vaccine was compared to an experimental vaccine and the adjuvant alone. For 
experimental vaccine cell suspensions of Cff, Cfv and Cfvi, obtained from aborted heifers, were 
killed by formaldehyde and emulsified with the oleo adjuvant. Natural exposure was for 90 days 
and half of the heifers in each group were additionally challenged by intra-vaginal inoculation 
with Cfv. Vaccinated heifers resisted or quickly cleared the infection, had higher pregnancy rates 
and higher systemic immune responses than control animals [150]. However, one of earlier 
studies on 321 bulls demonstrated superior protection of monovalent vaccine, when Cff was used 
as an antigen instead of Cfv [41]. In other hand, the local strain of Cff was utilized and diagnosis 
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was based on FAT and culture on selective media, making that conclusion doubtful in the 
modern time, when more advanced diagnostic methods can be implemented. 
The factors that influence effectiveness of vaccination are: animal age, frequency of booster 
vaccination, and adjuvant used. Heifers, vaccinated as yearlings, derived greater protection than 
those, vaccinated as calves. Two subcutaneous (SQ) injections of a similar vaccine, administered 
at 11 and 13 months of age gave greater protection than one injection [148]. Vaccines, prepared 
from the killed Cfv cells, grown on solid medium, gave greater protection than vaccines, 
prepared from Cfv, cultivated in liquid medium [149].   
There have been reports of utilizing monovalent vaccine with a purpose to cure BGC infection. 
In the 1973 study, 70% of preputial samples cultured negative after the first and other 30% after 
the booster vaccination of 41 bulls [41]. Other studies suggested that active systemic 
immunization would be able to eliminate vaginal career state in heifers; however, due to small 
number of animals conclusion could not be made [68, 155]. Later, in 2005 a Cfv bacterin in oil 
adjuvant was tested on 27 BGC-positive bulls; however, only half of them were cultured 
pathogen-free after two vaccinations [158]. Therefore, that method was recommended by authors 
as an additional strategy only [158].                
The role of adjuvants 
Recombinant or synthetic antigens in modern vaccines are generally less immunogenic than in 
older style vaccines, produced from live or killed whole organisms [159]. Therefore, in addition 
to such a relatively weak acquired immune response strong innate immunity must be elicited. 
Adjuvants are compounds that increase or modulate the intrinsic immunogenicity of an antigen, 
eliciting strong and long lasting immune responses.  
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Many recently developed adjuvants act via a TLR-dependent pathway. The initiation of Th cell 
responses requires 3 signals: 0, 1 or 2 [160]. In general, adjuvants can act on one or each of these 
signals, having various effector mechanisms (Table 1.4). Mucosal tissues could be protected by 
the initiation of Th cell responses, boosting Th17 cells that are produced in the presence of IL-23 
and characterized by production of IL-17, starting inflammatory response [161].  
The majority of BGC vaccines are prepared with oil or aluminum hydroxide adjuvants [16, 17, 
41, 145]. It has been suggested that vaccines made with oil adjuvants are the most effective [16, 
17, 41]. Alum was able to induce a good antibody response but had little capacity to stimulate 
cellular immunity. Alum could cause side effects such as sterile abscesses, eosinophilia and 
myofascitis [reviewed in 161]. Oil emulsions in systemic vaccination against STDs in bulls 
stimulated strong antibody and cell-mediated responses, but often caused injection site 
granulomas [159, 161]. However, newer oil adjuvants are much improved and might be used 
soon [159]. Alum generally induced an immunity of shorter duration than oil adjuvants [162]. 
Systemic immunization of 16 heifers with two commercial vaccines in aluminium hydroxide 
adjuvant with 3-week intervals and a subsequent 60-day natural challenge did not generate a 
significant rise in systemic antibody titers [145]. Bacterins in oil adjuvants have proven effective 
and provided long protection after a single dose [163].  
Polymer-based adjuvants have been developed in the last decade to enhance the immunogenicity 
of antigens and reduce the autoimmune responses. Given with an antigen, they induced humoral 
and cellular immune responses, although they did not induce such response on their own. 
Usually, they work on the principle of depot generation for slow release of the antigen, acting as 
an immuno-modulator via strong antigen presentation [reviewed in 164]. The polymer-based 
adjuvant usage in vaccines against bovine STDs remains the potential for the future.  
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1.6.  RESEARCH OBJECTIVES  
1. To compare the sensitivity and specificity of a real-time PCR assay, utilizing different sample 
preparation techniques, to direct culture of bovine vaginal mucus, confirmed by multiplex 
conventional PCR, for detection of Campylobacter fetus subsp. venerealis.  
2. To compare the proportion of heifers infected with Cfv, following natural exposure to infected 
bulls (assessed by culture and conventional PCR analysis of vaginal mucus) following 
vaccination with commercial vaccine, containing C. fetus antigen, and vaccinated with 
comparable vaccine without C. fetus antigen. 
3. To compare the proportion of, and days to pregnancy loss, between heifers vaccinated with 
commercial vaccine, containing C. fetus antigen, or vaccinated with comparable vaccine 
without C. fetus antigen, using trans-rectal ultrasonography and measurement of pregnancy-
associated glycoprotein concentration in serum. 
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Table 1.1. Worldwide prevalence estimates of Bovine Genital Campylobacteriosis 
Continent/ 
Country 
N Samples Test Sub- 
species  
Prev
% 
Reference 
E
u
ra
si
a 
Belgium 329 Prepuce samples DFAT/ 
culture 
NS  12.5 Bouters et al. 1973 
[41]. 
UK 190 Placentas, 
aborted fetuses  
ELISA/ 
culture 
Cff 40.5 Devenish et al. 
2005 [42]. 
China 80 Placentas, 
aborted fetuses  
PCR 
16SrRNA 
NS 0 Yang et al. 2012 
[25].  
A
fr
ic
a 
Namibia 1201 Prepuce samples PCR 
16SrRNA 
NS 2.1 Madoroba et al. 
2011 [27]. 
Nigeria 585 
104 
Prepuce samples 
Vaginal mucus 
Culture Cfv 2.1 
0.9 
Bawa et al. 1991 
[26].  
170 
100 
Prepuce samples 
Vaginal mucus 
Culture Cfv 1.8 
3.1 
Mshelia et al. 2012 
[28].  
602 Prepuce samples Culture Cfvi 12.3 Mai et al. 2013 
[38].  
S. Africa 87 Prepuce samples Culture Cfvi 17.2 Pefanis et al. 1988 
[37]. 
1912 Prepuce samples PCR 
16SrRNA 
NS 1.8 Madoroba et al. 
2011 [27]. 
Tanzania 58 Prepuce samples Culture Cfv 5.1 Swai et al. 2005 
[165].  
Zambia 41 Prepuce samples PCR 
16SrRNA 
NS 2.4 Madoroba et al. 
2011 [27]. 
N
o
rt
h
 A
m
er
ic
a 
Canada 67 Prepuce samples DFAT/ 
culture 
NS 29.8 Ruckerbauer et al. 
1974 [43] 
105 Prepuce samples DFAT/ 
culture 
NS 16 Garcia et al. 1983 
[44]. 
200 Prepuce samples DFAT/ 
culture 
NS 0.5 Finlay et al. 1985 
[36]. 
529 Prepuce samples ELISA/ 
culture 
Cff 3.4 Devenish et al. 
2005 [42].  
377 Prepuce samples PCR parA Cfv 2.9 Chaban et al. 2012 
[13] 
S
o
u
th
 A
m
er
ic
a 
Argentina 6764 Prepuce samples DFAT NS 0.9 Fort et al. 2004 
[45]. 
29 Vaginal mucus 
(buffalo) 
DIFT  NS 17 Cipolini et al. 2009 
[46]. 
Brazil 327 Prepuce samples DFAT NS 52.3 Pelegrin et al. 2002 
[29].  
Colombia 146 Prepuce samples Culture Cfv 14.9 Griffiths et al. 1984 
[39]. 
Australia 504 Prepuce samples Culture Cfv 4.1 Turnbull et al. 1977 
[40].  
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Table 1.2. Described transport and enrichment media (TEM) for Campylobacter fetus 
Media 
name 
Developed 
or first used 
for Cfv by 
Containing Properties, usage, advantages and 
issues 
Buffered 
saline 
McMillen et 
al. 2006 
[126]. 
Distilled water, 
sodium chloride  
Can be used when Cfv viability is not 
required [126] or for culturing when 
samples are kept slightly warm for a short 
period of time [13]. 
 
Australian 
TEM 
Clark et al. 
1978 [166]. 
Serum, antibiotics,  
antifungals 
Can be utilized for transportation for no 
longer than 48 hours at 18–37°C [166]. 
One report suggested Cfv viability for 24 
hours [167], another for 96 hours [168]. 
 
Weybridge 
TEM 
(WTEM) 
de Lisle et al. 
1982 [167].  
Blood, charcoal, 
antibiotics, 
antifungals 
Keeps viability for about four days at 
room temperature or refrigerated [167]. 
Indicated significantly better isolation 
rate for 4-hour transport compared to 
other media [88]. 
 
Modified 
Weybridge 
TEM 
(mWTEM) 
Lender et al. 
1990 [169]. 
Blood, charcoal, 
antibiotics, 
antifungals, FBP 
(Sodium pyruvate, 
Sodium 
metabisulphite, 
Ferrous sulphate) 
Maintained the viability for three days 
and supported their multiplication [169]. 
Allowed detection when only 10 
organisms were inoculated [140]. Proved 
50% more efficient than Australian TEM 
due to less polymixin B, which could 
inhibit Cfv [92]. Doesn’t completely 
control overgrowth of Pseudomanas spp. 
[93, 140]. 
 
Thomann 
TEM 
Hardwood et 
al. 2009 
[136]. 
Nutrient broth, FBP, 
antifungals, reduced 
mWTEM antibiotics 
concentration  
Promised survival time up to 8 days at 8–
37°C would improve diagnostic 
capabilities in endemic areas [136].  
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Table 1.3. Summary of vaccine trials for Bovine Genital Campylobacteriosis 
Country Australia 
Vaccine Monovalent 46 mg of 
Cfv cells in mineral oil 
adjuvant 
Monovalent 
commercial, Cfv cells 
in mineral oil adjuvant 
Monovalent commercial, 
Cfv cells in mineral oil 
adjuvant 
Animals and 
treatment 
4 Aberdeen Angus bulls, 
4-6 years old;     
334 heifers, 2 years old 
(Tx*=224, C*=100); 
261 heifers, 2 years old 
(Tx=157, C=104); 70 bulls 
Random 
assignment  
No Yes Yes 
Vaccination 
route 
2 SQ*, 5 weeks interval. 2 SQ, 5 weeks interval 2 SQ, 5 weeks interval. 
Challenge Culture infusion: 6 
months PV*; each bull 
was mated to 3-4 virgin 
heifers.   
Natural exposure PV to 
non-vaccinated bulls for 
28 days 
Natural exposure PV to 
vaccinated bulls for 70 
days 
Assessment 
of outcome 
Not blinded Blinded Blinded 
Results No positive samples 
from bulls and heifers. 
Pregnant: Tx=76%, 
C=55%; Non-pregnant 
in anoestrus: Tx=11%, 
C=6%.  
Pregnant: Tx=85%, 
C=61%;  
Concluded that 
vaccination of bulls did 
not improve pregnancy 
rate in heifers.  
Statistical 
analysis  
No P-value reported P-value reported 
Conclusion**  Effective Effective Heifers: effective; 
bulls: questionable  
Reference Clark et al, 1968 [17] Allan and Mutch, 1971 
[151] 
Allan, 1972 [152] 
*Tx-treatment group, C-control group; PV-post vaccination; SQ- sub-cuteniously; 
** by authors 
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Table 1.3. Summary of vaccine trials for Bovine Genital Campylobacteriosis (continued) 
Country Australia 
Vaccine Monovalent, bacterins: Cfv 
isolated from infected heifer 
and grown in solid (A, B) 
and liquid (C, D) media.  
Monovalent, Cfv cells 
grown in liquid medium, 
prepared with mineral oil 
adjuvant.  
Monovalent 40 
mg of Cfv cells 
cultured in liquid 
media 
Animals and 
treatment 
125 Hereford heifers, 5 equal 
groups: A, C – 11-13 months 
old, B, D – 17-19 months 
old, E-control.     
80 Hereford heifers, 6 
groups: A=17, B=17, C=16 
(11-13 months old); D=10, 
E=10, F=10 (5-8 months 
old). C, F-control.      
102 Aberdeen 
Angus cows, 2 
years old; 
(Tx*=68, 
C*=34);  
Random 
assignment  
Yes Yes Yes 
Vaccination 
route 
1 SQ * Groups A,D: 1 SQ; 
B,E: 2 SQ, 2 months interval 
1 SQ 
Challenge Natural exposure PV* for 3 
mating seasons.  
Culture infusion: at the 1
st
 
service.  
Natural exposure PV for 60 
days at the age of 19-22 
months. Culture infusion: 
within 2 h of the 1
st
 service. 
Natural exposure 
to carrier bulls 1-
2 months PV 
Assessment 
of outcome 
Blinded Blinded Blinded 
Results Infected: groups: 1
st
 season: 
A=2/22, B=1/24, C=7/22, 
D=0/25, E=15/23; 2
nd
 
season:  A=3/16, B=3/17, 
C=5/12, D=3/17, E=12/14; 
3
rd
 season: A=3/25, B=2/25, 
C=2/25, D=3/25, E=10/10.  
Pregnant: A=91%, B=92%, 
C=77%, D=88%, E=39%; 
2
nd
 season:  A=94%, 
B=100%, C=92%, D=94%, 
E=43%; 3
rd
 season: A=91%, 
B=100%, C=86%, D=75%, 
E=20%.  
Infected: groups: 
A=7/16, B=5/17, C=12/14, 
D=8/8, E=7/10, F=10/10;  
Pregnant: A=69%, B=88%, 
C=43%, D=50%, E=70%, 
F=20%;  
 
Calving in time: 
Tx=82%, 
C=59%; non-
challenged=84%;  
late calving or 
non-pregnant: 
Tx=18%, 
C=41%, non-
challenged=16%. 
Statistical 
analysis  
P-value reported P-value reported P-value reported  
Conclusion**  Effective  Effective 
Reference Clark et al, 1972 [149] Clark et al, 1972 [148] Clark et al, 1972 
[146] 
*Tx-treatment group, C-control group; PV-post vaccination; SQ - sub-cuteniously; 
** by authors 
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Table 1.3. Summary of vaccine trials for Bovine Genital Campylobacteriosis (continued) 
Country Australia 
Vaccine Monovalent 40 mg of cells 
cultured in liquid medium 
(Tx1*– Cfv, Tx2 –Cfvi cells 
Monovalent 
commercial,   Cfvi 
cells in repository 
adjuvant 
Bivalent commercial, 
20 mg Cfv and Cfvi 
cells in mineral oil 
adjuvant 
Animals and 
treatment 
80 Hereford heifers, 20-28 
months old (Tx1=20, 
C*1=20) and 20-28 months 
old (Tx2=17, C2=20); 13 
bulls, 14-18 months old 
(Cfv vaccine), 7 bulls, 3 
years old (Cfvi vaccine) 
33 Guensey heifers, 12-
14 months old (Tx=23, 
C=10);  
24 Hereford bulls, 2.5-4 
years old (Tx=12, 
C=12); 
Random 
assignment  
Yes No Yes 
Vaccination 
route 
Heifers: 1 SQ *; bulls: 2 
SQ, 8 weeks interval. 
1 SQ 2 SQ, 6 weeks interval.   
Challenge Culture infusion: 
of 10
7
-10
8 
Cfvi cells for 8 
weeks PV* 
Culture infusion of 10
8
 
Cfvi cells into the 
fornix of vagina, 30 
days PV 
Culture infusion: 
2 years PV all bulls, 3 
years PV 9 bulls in each 
group 
Assessment 
of outcome 
Blinded Not blinded Not blinded 
Results Infected:  Tx1=12/20, 
C1=20/20, Tx2=2/17, 
C2=19/20; bulls: 6/13 and 
6/7.  
Pregnant: Tx1=15/20, 
C1=9/20, Tx2=15/17, 
C2=16/20;   
Significant titers rise 
(serum agglutination 
test) in Tx heifers. 
Cultured positive 
(weekly swabs): 
Tx=3/23, C=8/10 
Infected: in 2 years 
Tx=3/12, C=0/12; in 3 
years: Tx=4/9, C=7/9; 
Recommended: bi-
annual booster   
Statistical 
analysis  
P-value reported P-value reported No 
Conclusion**  Effective Effective Effective 
Reference Clark et al, 1976 [153] Johns et al, 1977 [147] Clark et al, 1982 [154] 
*Tx-treatment group, C-control group; PV-post vaccination; SQ - sub-cuteniously; 
** by authors 
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Table 1.3. Summary of vaccine trials for Bovine Genital Campylobacteriosis (continued) 
Country USA 
Vaccine Monovalent 20 mg/ml 
Cfv cells in incomplete 
Freud adjuvant 
Monovalent; A. Whole 
cell vaccine: 20 mg of 
Cfv cells; B. water 
extract vaccine: 
supernatant; C. 
“ribosomal” vaccine: 
broken cells. 
Monovalent commercial, 
41 mg Cfv cells 
Animals and 
treatment 
16 virgin Holstein-
Friesen heifers (Tx*=8, 
C*=8 (4-adjuvant only, 
4-non vaccinated));  
32 virgin Holstein - 
Friesian heifers (8-
vaccine A, 8-vaccine B, 
8-vaccine C, 8-saline).  
12 Angus bulls, 5 years 
old (2-non-infected, 10-
infected: Tx=6, C=4);  
 
Random 
assignment 
No No Yes 
Vaccination 
route  
1 SQ *. 2 SQ days 14-24 post-
infecting. 
2 SQ, 4 weeks interval.   
Challenge Culture infusion 12-24 
h after heat observed.  
Culture infusion before 
vaccination  
 
Culture infusion;  
Natural exposure to virgin 
heifers PV (non-
infected=6, Tx=18, C=15.) 
Assessment 
of outcome 
Not blinded Not blinded Not blinded 
Results Agglutination test: titers 
increased in Tx animals 
Infected: Tx=2/8 (25-48 
days PV*), C=8/8 (48-
51 days PV). Active 
immunization 
eliminates BGC vaginal 
carrier state. 
Agglutination test: titers 
increase in vaccinated 
heifers.  
Infected: whole cell 
vaccine=2/8, water 
extract vaccine=2/8, 
“ribosomal” 
vaccine=2/8, 
saline=8/8.   
Tube agglutination test: 
increase in serum Ab titers 
in vaccinated bulls.   
Infected: non-
infected=0/2, Tx=0/6, 
C=4/4; exposed heifers 
infected: non-infected=0/6, 
Tx=0/18, C= 12/15. 
Statistical 
analysis  
No Descriptive only  P-value reported 
Conclusion**  Effective Effective Effective 
Reference Shurig et al, 1975 [68] Shurig et al, 1978 [155] Vasquez et al, 1983 [156] 
*Tx-treatment group, C-control group; PV-post vaccination; SQ - sub-cuteniously; 
** by authors 
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Table 1.3. Summary of vaccine trials for Bovine Genital Campylobacteriosis (continued) 
Country Jamaica Brazil 
Vaccine Monovalent, Cfv 
(Jamaican stran) 
Monovalent, 2.5 ml 
suspension of Cff cell 
in incomplete Freud 
adjuvant 
Monovalent, Cfv bacterin 
with 15% of oil adjuvant 
added. 
Animals and 
treatment 
46 non-pregnant 
yearling heifers 
(Tx*=13, C*=13);  
4 bulls , 2 years old 
321 bulls (41-positive 
for Cfv, 288-negative 
for Cfv);  
  
27 Nelore bulls, tested 
positive by DFAT;  
Random 
assignment 
No No No 
Vaccination 
route 
SQ * Curative: 2 s/c, 6 weeks 
interval; preventive: 1 
SQ.      
curative: 2 SQ, 23 days 
interval;    
Challenge Natural exposure of 
bulls to infected  
heifers 
Natural exposure in 
infected areas for 1 
year PV* for 288 
negative bulls.   
Were tested positive 
before the trial 
Assessment 
of outcome 
Not blinded Not blinded Not blinded 
Results Infected heifers: 
Tx=33%, C=68%; 
Pregnant: culture 
negative=72%, culture 
positive=29% 
Infected bulls= 0/4 
 
Positive bulls: 30/41-
free after first injection, 
11/41-free after the 
second injection.  
None of negative bulls 
were infected.   
Infected: 15/27-after 1-st 
vaccination, 12/27-after 2-
nd vaccination.  
Recommendation: as an 
additional strategy.   
Statistical 
analysis  
No No P-value reported 
Conclusion**  Effective Effective Questionable effectiveness 
Reference Eaglesome et al, 1986 
[157] 
Bouters et al, 1973 [41] Foscolo et al, 2005 [158] 
*Tx-treatment group, C-control group; PV-post vaccination; SQ - sub-cuteniously; 
** by authors 
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Table 1.3. Summary of vaccine trials for Bovine Genital Campylobacteriosis (continued) 
Country Argentina 
Vaccine Polyvalent,  
Vac A*: L. interrogans, H. 
somnus, Cfv, Cff, IBRV, BVDV 
in aluminium hydroxide adjuvant  
Vac B: same as Vac A, except H. 
somnus.   
 Vac A (commercial): T. foetus, Cfv, L. 
interrogans;  
 Vac B (experimental): T. foetus, Cff, 
Cfv, Cfvi (from aborted heifers) in oleo 
adjuvant.    
Animals and 
treatment 
24 Aberdeen Angus , Hereford, 
cross-breed heifers, 27 months 
old (Vac A=8, Vac B=8, C*=8); 
62 Aberdeen Angus Hereford, cross-breed 
heifers, 18-24 months old (Vac A=21, Vac 
B=20, C=21); 
Random 
assignment 
Yes Yes 
Vaccination 
route 
two SQ *, 3 weeks interval Vac A: SQ 60 and 30 days before 
breeding; Vac B: SQ +i/vaginal 30 days 
before and 15 days after breeding; C: 
adjuvant, same method as Vac A.   
Challenge Natural exposure PV* to infected 
bull for 60 days. 
Natural exposure to infected bull for 90 
days Vac A1=11, Vac B1=10, C1=10;   
Natural exposure+ culture infusion on day 
30 of breeding (Vac A2=10, Vac B2=10, 
C2=11).  
 
Assessment 
of outcome 
Not blinded Not blinded 
Results IFAT results: no important titers 
increase, slight increase after 
breeding. 
ELISA results: slight titers 
increase.   
Pregnancy: Vac A=2/8, 
VacB=3/8, C=0/8.  
Results are limited due to low 
number of animals. 
Significantly higher ELISA titers in Vac B 
heifers compare to Vac A and C. Infected:  
Vac A1=7/11, Vac B1=4/10, C1=8/10; Vac 
A2=3/10, Vac B2=7/10, C2=9/11.  
Pregnant: Vac A1=4/11, Vac B1=7/10, 
C1=2/10; Vac A2=5/10, Vac B2=8/10, 
C2=6/11. Experimental vaccine – faster 
rise in systemic Ab and better pregnancy 
rate. 
Statistical 
analysis  
Kappa and P-value reported P-value reported 
Conclusion**  Not effective Effective, experimental – superior effect 
Reference Cobo et al, 2003 [145] Cobo et al, 2004 [150] 
* Vac-treatment group, C-control group; PV-post vaccination; SQ - sub-cuteniously; 
** by authors 
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Table 1.4. Types of vaccine adjuvants and mechanisms of action 
Adjuvant 
type 
Characteristics Examples 
Type A Specific agonist for TLRs. Acts primary on signal 
0, indirectly on signal 2, activating APCs and 
triggering secretion IL-12 [160]. Can act on signal 1 
[170].   
 
Monophosphoryl lipid A 
(MPL)  
Type B Non-specific. Build a depot at the injection site, 
leading to high local antigen concentration and 
improving uptake by APC [171].   
Aluminium hydroxide, MF59, 
Liposomal adjuvants, Freud 
adjuvants, Nanoparticles, 
Toxin-derived adjuvants  
 
Type C Enhance signal 2 through interaction with co-
stimulatory molecules on APC. Limited clinical use 
[159].    
 
TGN1412 
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2.1. ABSTRACT 
Introduction — The laboratory diagnosis of Bovine Genital Campylobacteriosis is complicated 
by the proper identification of Campylobacter fetus subspecies. Although culture is still the gold 
standard, PCR-based methods have been shown to be a good choice for the detection of 
Campylobacter fetus subsp. venerealis (Cfv). Successful Cfv detection is dependent on both the 
PCR assay used and the sample preparation technique.  
Objective — To compare Cfv real-time PCR results for bovine vaginal mucus samples, prepared 
using heat lysis and magnetic bead based sample preparation techniques, to results of direct, 
selective culture, confirmed by multiplex conventional PCR.   
Study design — Cross-sectional study 
Animals — 50 crossbred beef heifers  
Materials and methods — Vaginal mucus samples, collected weekly from weeks 4–7 of 
exposure to infected bulls, were cultured, frozen and subsequently processed for real-time PCR. 
Initially, real-time PCR results from 50 samples, prepared with four variations of a heat lysis 
protocol, were compared to culture. These were modifications of a previously described method 
for bovine preputial samples (Chaban et al. 2012. Can J of Vet Res; 76: 166). The two heat lysis 
protocols with the fewest dilution steps generated the most positive and fewest ambiguous test 
results and were subsequently compared to culture, confirmed by multiplex conventional PCR, 
and to results of real-time PCR on 200 samples, prepared with a commercial magnetic bead-
based extraction kit.  
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Results — The magnetic bead-based protocol demonstrated higher sensitivity (Sens=48.4%, 
P=0.02) and lower specificity (Spec=78.9%, P=0.01) than the first heat lysis protocol 
(Sens=29.4%, Spec=88.2%), but had no significant differences with the second heat lysis 
protocol (Sens=35.0%, P=0.16; Spec=81.1%, P=0.62).  
Conclusions and future research — Overall, the heat lysis sample preparation method, 
designed for bovine preputial samples, did not work well for vaginal mucus. All modifications of 
that protocol and magnetic bead-based extraction protocol had low sensitivity, compared to 
culture under ideal conditions. More research is needed on fresh vaginal mucus samples where 
PCR and culture are done concurrently.     
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2.2. INTRODUCTION 
 
Campylobacter fetus subsp. venerealis causes venereal infections in cattle, where inflammation 
in the female genital tract causes abortion, temporary infertility and prolonged estrus cycle. 
Campylobacter fetus is divided into the subspecies C. fetus subsp. venerealis (Cfv) and C. fetus 
subsp. fetus (Cff), and Cfv can have a biovar "intermedius” (Cfvi). Cfv is highly adapted to the 
genital tract [1–3], while Cff is mainly isolated from the gastrointestinal tract and only 
sporadically associated with abortions. Cff can also be recovered from the genital tract with no 
associated clinical symptoms [1]. Therefore, the subspecies differ in their epidemiology and 
clinical importance, and accurate differentiation is essential but can be difficult.  
There are several diagnostic techniques for detection and differentiation of C. fetus; however, 
each has limitations. For successful culture, the organism must be viable. Campylobacter 
requires special transport conditions, and samples need to be cultured soon after collection or 
placed into transport media. Isolation of Cfv from preputial secretions was achieved with equal 
success from samples kept in the modified Stuart's transport medium at 4°C to 6°C for 48 hours 
and from newly collected samples [4].  
The Polymerase Chain Reaction (PCR) is a modern diagnostic tool for detecting C. fetus and 
believed to be able to distinguish subspecies. Hum’s PCR is based on two PCR primer sets [5]. 
One primer set is MG3F/MG4R, which amplifies a 960 base pair (bp) [3] or 750 bp fragment [6] 
of the C. fetus carbon starvation protein gene, present in both subspecies. The second primer set 
is VenSF/VenSR, which amplifies a 142 bp fragment of the parA gene in Cfv [7].  
A recent study by McGoldrick et al. reported the successful development of two real-time SYBR 
Green PCR assays that can detect C. fetus (by targeting 140 bp of nahE gene) and discriminate 
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Cfv from Cff (by targeting 150 bp of ISCfe-1) from cultured colonies [8]. However, these assays 
were validated only on isolates, but a technique that could be directly used on bovine preputial 
and vaginal mucus samples would be more convenient.  
It is not only the identification of an appropriate Cfv-specific gene that is important for 
successful diagnosis, but also the sample preparation protocol. We anticipated that a heat lysis 
technique, successfully used on preputial scrape samples [7], would work on vaginal mucus, but 
might require some modification.  
There are differences in the consistency and composition of bull preputial and cow vaginal 
mucus samples. The composition of cervical-vaginal mucus (CVM) is likely less variable than 
the mixture of smegma, blood, epithelial cells, urine and feces in preputial samples, but is often 
more viscous. The consistency of vaginal mucus also depends on the stage of reproductive cycle 
at the sampling time [9].  
Extraction of nucleic acids from mucus samples has been improved by using magnetic beads 
[10]. Magnetic beads offer many benefits, compare to other sample preparation technologies, 
since the extraction procedure combines effective steps for disrupting samples that are difficult 
to lyse. As an example, one such nucleic acid isolation methods employs mechanical disruption 
of samples with zirconia beads in a guanidinium thiocyanate-based solution that rapidly releases 
nucleic acids while it simultaneously inactivates nucleases in the sample matrix [10, 11]. 
Samples are than diluted with isopropanol and paramagnetic beads are added. The surface of 
these beads is modified for binding of nucleic acids. The beads with nucleic acids are 
immobilized on magnets and washed to remove proteins and other contaminants. A second wash 
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removes residual binding solution and the nucleic acid is eluted in a small volume of low salt 
buffer [11].     
The objective of the study was to compare Cfv real-time PCR results for samples, prepared using 
heat lysis and magnetic bead based sample preparation, to results of direct, selective culture of 
bovine vaginal mucus.  
 2.3. MATERIALS AND METHODS 
2.3.1. Sample collection 
All procedures were performed in accordance with the Canadian Council of Animal Care and 
approved by the University of Saskatchewan Animal Research Ethics Board (protocols 
#20100061 and #20100077).   
Vaginal mucus samples were collected from 50 cross-bred beef heifers in weeks 4, 5, 6, 7 of 
exposure to two Cfv-infected Black Angus bulls. During the collection, heifers were restrained in 
a manual squeeze chute. Sampling was performed by aspiration using a 25” pipettea, connected 
to a 20 ml syringe. Prior to aspiration, approximately 2 ml of phosphate-buffered saline (PBS) 
was passed through the pipette into the syringe. The pipette was then placed inside a solid 12” 
plastic AI sheath protector
b
 to minimize fecal contamination. Once the aspiration of mucus was 
complete, the pipette was withdrawn and rinsed into a 4 ml cryovial tube, containing 2 ml of 
PBS. Cryovials were transported back to the lab in a styrofoam box with warm water bags within 
2 h of collection (25 °C).  
A portion of each sample was cultured upon arrival to the laboratory, while the rest of samples 
were frozen at -70 °C for subsequent real-time PCR.    
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2.3.2. Laboratory testing  
Culture of samples, confirmed by multiplex conventional PCR 
Upon arrival at the laboratory, an aliquot of 300 μl was spread onto a 0.65 µm mixed cellulose 
ester membrane filter
c
, placed on 5% blood agar plates, equally covering entire surface of the 
filter. Incubation was done at 37 °C under microaerobic conditions with an integrated chemical 
packs for rapid waterless and catalyst-free CO2 generation
d
. Plates were examined after 72 h of 
incubation and colonies consistent with Campylobacter morphology were Gram stained. Plates 
that contained no evidence of Campylobacter colonies were incubated for an additional 72 h. 
Colonies with Gram stain results, consistent in morphology with Campylobacter, were subjected 
to a conventional multiplex PCR using the primers MG3F/MG4R and VenSF/VenSR as 
previously described [3].   
Comparison of sample processing protocols 
We recognized that culture followed by Gram-staining and colony morphology, and confirmed 
by multiplex conventional PCR remains the “gold standard” test from a regulatory standpoint. 
However, it was found in a previous study that a PCR assay was more sensitive in preputial 
samples, collected from Cfv-infected bulls [7].  
Initially, 50 samples from the week of bull exposure with the biggest proportion of culture 
positive results were tested using four heat lysis sample preparation protocols (Table 2.1). The 
procedures were variations of a protocol previously used for bull prepuce samples [7] and 
originally modified from McMillen et al. (2006) [12]. For an extraction negative control, 200 µl 
of ultrapure water was processed with every batch of samples in the same way as the samples.  
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The same real-time PCR assay was performed on 200 vaginal mucus samples from the 50 heifers 
in weeks 4, 5, 6, 7 of exposure to infected bulls. Samples were prepared for PCR with the two 
heat lysis sample processing protocols that demonstrated higher sensitivity and a larger number 
of detected positives, as well as with the nucleic acid extraction protocol that utilized a 
commercial magnetic bead-based sample disruption kit
e
 (Table 2.1).  PCR results were compared 
to culture results.  
Real-time PCR technique  
All real-time PCR tests were completed with SYBR Green real-time PCR technique as described 
by Chaban et al. in 2012 [7], using the VenSF/VenSR primer set. All samples were tested in 
duplicates. The master mix solution for each reaction included 12.5 μl of SYBR Green mixf, 1 μl 
(400nM) of forward primer
g
, 1 μl (400nM) of reverse primerh, 8.5 μl of ultrapure water, and 2 μl 
of template DNA, in a final volume of 25 μl.   
 A standard curve was used in order to appreciate the efficiency of PCR reaction. The standard 
curve consisted of a dilution series of a plasmid containing the 142 bp Hum insert. The dilution 
series started with 10
7 
plasmids/reaction and sequentially decreased concentrations to end with 
the least concentrated plasmids, 10
0
 plasmids/reaction.  
Samples were considered positive if both duplicates had a threshold cycle value and the melt 
curve contained a specific product peak. For melt curve analysis the melting temperature of 
78.5±0.5°C was considered as specific for Cfv PCR product on the thermocycler
i
. Samples were 
considered negative if no threshold cycle was recorded or if the melt curve analysis showed a 
non-specific product peak for both replicates. Samples were called “suspicious” when one 
duplicate met the negative criteria and another tube met the positive criteria.  
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All suspicious samples were tested a second time by the same PCR assay, using the same sample 
preparation protocol. Those that remained suspicious after the second run were tested once again 
by the same PCR assay, using the same sample preparation protocol, and only clear positive ones 
were called positives; others were called negatives.  
2.3.3. Statistical analyses 
All data were entered into a spreadsheet and analyzed using commercial statistical software
j
. 
Descriptive statistics and comparisons were performed.  
Cohen’s kappa coefficient was calculated in order to measure the agreement between the results 
of vaginal mucus culture based on morphology and conventional PCR of the colonies consisted 
in morphology with C. fetus [13].   
To account for the correlation within samples and heifers because every heifer was sampled 
more than once and each sample was processed more than once, the sensitivity and specificity 
was analyzed with generalized estimating equations (GEE) logistic regression model in order to 
correct possible violations of the independence assumption. For sensitivity, culture-positive 
samples were selected and then a logistic regression model created with one predictor (test 
type). For specificity, the culture-negative samples were selected but real-time PCR results 
variables were coded in an opposite way to be sure to get specificity, not the false positive rate. 
A 95% confidence interval for sensitivity was calculated for each method. The same actions 
were also done for specificity.  
All models were assessed for outliers and goodness of fit. Differences were accepted as 
statistically significant at the 95% confidence limit when P<0.05 [13].  
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2.4. RESULTS 
2.4.1. Results of culture, confirmed by multiplex conventional PCR 
The results of culture of vaginal mucus from the heifers, collected in weeks 4–7 of exposure to 
the Cfv infected bulls (Table 2.2), demonstrated that week 6 had the largest proportion of 
positives (Week 4, 30%; Week 5, 24%; Week 6, 38%, Week 7, 24%). Therefore, the samples of 
week 6 were chosen to process with four heat lysis sample preparation protocols. In this study 
culture positive results based on morphology were consequently confirmed by multiplex 
conventional PCR assay. There was moderate agreement (kappa=0.48, 95% CI: 0.48–0.49) 
between the results of two diagnostic methods when compared in weeks 4–7 of exposure.   
2.4.2. Comparison of heat lysis sample preparation protocols 
The results of real-time PCR where samples were processed with four heat lysis protocols, 
demonstrated that protocols III and IV were easier to perform, had a higher proportion of 
detected positives (Protocol I, 6%; Protocol II, 14%; Protocol III, 16%; Protocol IV, 16%) and a 
lower number of suspicious results (Protocol I, 16%; Protocol II, 18%; Protocol III, 6%; Protocol 
IV, 12%) than protocols I and II (Table 2.3a). When suspicious samples were processed again 
with the same protocol, there were more reduction of suspicious results, particularly in protocols 
I and II (Table 2.3b). The remaining suspicious samples were processed one more time and all of 
them were negative.  
Protocol I had the lowest number of test-positive results and none of them were cultured positive 
(Table 2.4). The crude sensitivity of protocol IV was 1.5 times higher than that of protocol II and 
1.2 times higher than that of protocol III. However, logistic regression analysis did not detect 
significant difference in sensitivity between protocols IV and II (P=0.46) and protocols IV and 
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III (P=0.72). The crude specificity of protocol I was the same as protocol II, and protocol III was 
the same as of protocol IV. Logistic regression analysis did not detect a significant difference in 
specificity between protocols (P=0.69).  
Therefore, protocol III and IV were the best choices for further comparison to the nucleic acid 
extraction protocol (Protocol V) that utilized a commercial magnetic bead-based sample 
disruption kit
e
 because of higher crude sensitivity and larger number of detected positives.  
2.4.3. Comparison of heat lysis sample preparation protocols to magnetic bead-based 
extraction method  
To compare heat lysis sample preparation protocols III and IV to Protocol V (magnetic bead-
based extraction), 200 samples were processed with these three methods. Protocol V 
demonstrated the largest proportion of detected positives (Protocol III, 19.5%; Protocol IV, 
15.5%; Protocol V, 21%) and suspicious test results (Protocol III, 9.5%; Protocol IV, 15.5%; 
Protocol V, 20.5%) compare to culture (Table 2.5a).  
All suspicious samples were tested a second time using the same protocol and the number of 
suspicious results reduced in all protocols, but Protocol V had the largest reduction (Table 2.5b). 
The remaining suspicious samples were processed one more time and all of them tested negative 
(Table 2.6).  
Logistic regression GEE model analysis demonstrated that the sensitivity of Protocol V (48.4%) 
was significantly higher than protocol IV (29.4%) (P=0.02) and tended to be higher than Protocol 
III (35%) (P=0.16). However, Protocol V had significantly lower specificity (78.9%) than 
Protocol IV (88.2%) (P=0.01), but there was no significant difference in specificity between 
Protocol V (78.9%) and Protocol III (81.1%) (P=0.62).   
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2.5. DISCUSSION 
In this study the results of Cfv real-time PCR were compared for bovine vaginal mucus samples, 
prepared using heat lysis and magnetic bead based sample preparation techniques, to results of 
direct, selective culture of the same samples. The sample processing method, designed and 
successfully applied for bull preputial samples [7], demonstrated relatively low sensitivity 
compared to culture, confirmed by multiplex conventional PCR, when tested on vaginal mucus 
samples in this study. All modifications of that heat lysis protocol demonstrated low sensitivity 
when were compared to culture, confirmed by conventional PCR; however, the most satisfactory 
results were achieved with protocols involving fewer processing steps. The magnetic bead-based 
extraction method tended to be the comparatively more sensitive than heat lysis methods but 
required too much time and resources to be practical for routine use. 
The preputial samples mostly consisted of smegma and blood; therefore, the DNA isolation 
protocol designed for preputial samples contained several steps with a purpose to eliminate 
possible inhibitors [7]. Bovine CVM comprises two phases: aqueous and gel [14]. The aqueous 
phase contains low molecular weight compounds that are dissolved in up to 95% water [10]; the 
gel phase is formed mainly by insoluble high molecular weight glycoproteins (mucins) [14, 15]. 
These highly glycosylated proteins are probably the main factor, responsible for the rheological 
properties of CVM [15]. Biophysical and biochemical properties of CVM are controlled by sex 
steroids during the estrus cycle [14]. For instance, during the pre-ovulatory period CVM 
becomes less viscous and more hydrated, facilitating the posterior movement of spermatozoa 
during breeding [15], while in the luteal phase hydration decreases and viscosity increases, 
preventing spermatozoa migration [15–17].  
67 
 
CVM is secreted during the whole cycle, but its volume increases at estrus [17]. Noonan et al. 
noticed an inverse relationship between the dry matter content in CVM and the degree of 
crystallization [16]. Decreasing in proportion of salts such as NaCl, KCl and CaCl2 in the 
aqueous part of CVM leads to decreasing water content. Such changes cause a decrease in 
crystallization and a relative increase in other salt components in the dry residue. During the 
estrous cycle, the dry matter concentration in CVM reaches a minimum value on the day of 
estrus and a maximum value at the mid-cycle and increased from the day of estrus to the 19th 
day of gestation, while the extent of crystallization decreased. Crystallization occurred to the 
greatest extent on the day of estrus [17, 18]. Therefore, whenever CVM is collected it appears 
“gelly” due to either high viscosity or crystallization.   
We speculate that the biophysical properties of vaginal mucus may have caused DNA loss during 
the isolation process. Dilution steps in the heat-lysis protocol that were designed to reduce PCR 
inhibitors may have resulted in lost DNA. The gelatinous consistency of the mucus also made it 
difficult to accurately pipette and may have impacted the distribution of the organism and DNA 
in the sample. It seemed impossible to homogenate these samples prior to pipetting. Even though 
no quantitive analysis was performed, it can be appreciated from this study that heat lysis 
protocols, where pellet or supernatant were not discarded, had greater sensitivity.  
Different DNA isolation protocols can be utilized on clinical samples, collected from farms with 
a history of infertility. In one study [18], 94 CVM samples, collected mainly during the estrous 
cycle, were incubated in a transport enrichment medium (TEM) at 37°C for 5 days, and then 
processed with cetyltrimethylammonium bromide (CTAB) for DNA extraction for consequent 
Hum’s primer set-based PCR [5]. According to the authors the 5-day period of pre-enrichment in 
TEM provided a multiplication of the bacteria and increase in PCR detection and the CTAB 
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extraction protocol resulted in Cfv detection in 34% of samples [18]. In the same study, from 277 
prepuce samples, CVM and abomasum contents of aborted fetuses, 24% were tested positive for 
C. fetus using PCR, while only 2.8% were positive by bacterial isolation in culture [18]. This 
method required five days to perform and the large number of detected positives was most likely 
due to maintaining viability of the pathogen. The objective of our research, however, was to test 
rapid sample processing protocol for bovine CVM that can be used under field conditions when 
viability of Cfv could be compromised. 
The most satisfactory results were achieved with modified heat lysis protocols involving fewer 
processing steps. The two most sensitive protocols were compared to the magnetic bead-based 
extraction method. The magnetic bead-based nucleic acid isolation kit, used in this study, was 
designed for rapid high throughput purification of DNA and RNA for use in PCR applications. 
According to the manufacturer
e
 it can be utilized for different types of biological and 
environmental samples.  
All sample preparation methods for bovine vaginal mucus that were compared in this study had a 
low sensitivity and high specificity relatively to culture, which remains the gold standard 
according to the World Organization for Animal Health release of 2012 (19). More positives 
were detected by culture and confirmed by conventional PCR than by real-time PCR. In our 
study, culture was performed under ideal conditions: plating within four hours, and keeping 
reasonable environmental temperatures prior to plating. This allowed maintaining viability of 
Cfv, which is the biggest challenge under field conditions.  We then applied conventional PCR 
directly on the suspect colonies which increased the specificity of the culture. The agreement 
(kappa) between culture and conventional PCR was moderate in this study since many samples 
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were culture positive based on morphology but were negative accordingly to conventional PCR 
results.      
Even though the magnetic bead-based extraction method tended to be the most sensitive, it 
required much more time and resources to perform than the other two. The entire isolation 
procedure for bovine vaginal mucus with the commercial magnetic bead-based sample disruption 
kit required about 3 hours to perform. Protocol III was the easiest to perform and there was no 
statistically significant difference between Protocol III and V in sensitivity and specificity. The 
sample preparation method for PCR, developed for preputial samples, can be potentially utilized 
for vaginal mucus when all dilution steps are skipped.  
Our study has been performed on samples that were frozen and thawed several times since every 
sample was processed with different methods. Initially, PCR results of 50 samples, processed 
with four heat lysis protocols, were compared to the culture. Then, all 200 samples were 
processed with protocols III, IV and V. Protocols III and IV were performed at the same time. 
Protocol V was performed last.  
Rapid freezing results in intracellular ice crystal formation, causing membranes to rupture, 
whereas slow cooling allows water to leach out reducing crystal formation, but leads to cell 
rupture due to osmotic pressure imbalance. Ice crystal-induced damage to organelle structures 
leads to activation of rescue systems, associated with energy generation that results in production 
of free radicals and oxidative stress to DNA [20]. Intracellular (DMSO, glycerol, and ethylene 
glycol) or extracellular (sucrose, dextrose, and polyvinylpyrrolidone) cryoprotectants can be 
added to samples. Intracellular agents prevent the formation of ice crystals and extracellular 
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agents reduce the hyperosmotic effect during freezing [20]. Therefore, further testing of the 
DNA isolation methods should be performed utilizing cryoprotectants or on fresh samples.  
2.6. CONCLUSIONS 
The heat lysis sample preparation protocol, previously utilized for bovine preputial samples, 
required some modifications in order to adapt it to CVM. Release of DNA directly from a CVM 
sample by a modified heat lysis protocol (Protocol III) was easy to perform and gave a sensitivity 
of 35% and specificity of 81% in subsequent real-time PCR. A magnetic bead-based nucleic acid 
extraction protocoldemonstrated sensitivity of 48%; however, this protocol is time and resource 
consuming. Finally, these two methods should be further compared on fresh CVM samples in 
order to remove possible bias of freezing-thawing.   
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a
Continental Plastics, Vetsource Canada, Cambridge, ON; Item #E6-5415 
b
Continental Plastics, Vetsource Canada, Cambridge, ON; Item #B6-4775 
c
Millipore, Billerica, MA, USA 
dGasPak™ EZ Campy Pouch™ System, BD diagnostics, Mississauga, ON, Canada 
e
MagMAX
TM 
Total Nucleic Acid Isolation Kit (Bead-Based Sample Disruption), Applied 
Biosystems, Ambion; Part Number AM1840 
f
IQ SYBR Green Supermix, Bio-Rad Laboratories, Hercules, CA, 94547  
g
VenSF: 5'-CTT AGC AGT TTG CGA TAT TGC CAT T-3' [11] 
h
VenSR: 5'-GCT TTT GAG ATA ACA ATA AGA GCT T-3' [11] 
i
Bio-Rad MyiQ, Bio-Rad Laboratories, Inc. 
j
Stata 12 IC, Stata Corp., College Station, TX 
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Table 2.1. Sample processing protocols for vaginal mucus real-time PCR used in this study  
Protocol  Description 
I 1) 200 µl of sample was centrifuged in a microfuge tube for 5 min at 12 000 × g  
2) supernatant discarded  
3) 100 µl of ultrapure H2O was added directly on top of the pellet  
4) vortexed for ~5 seconds   
5) heated at 95°C in a water bath for 10 min  
6) centrifuged 30 seconds at 2 000 × g  
7) 20 µl of supernatant was added to 180 µl of ultrapure H2O (1:10 dilution) [7]. 
II Same as protocol I, but step 7 was skipped 
III 1) 200 µl of sample was heated at 95°C in a water bath for 10 min  
2) centrifuged 30 seconds at 2 000 × g 
IV 1) 200 µl of sample was heated at 95°C in a water bath for 10 min  
2) centrifuged 30 seconds at 2 000 × g   
3) diluted 1:10 
V Samples were processed according to the manual for the commercial magnetic bead-based 
nucleic acid isolation kit
e
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Table 2.2. Results of vaginal mucus samples culture, confirmed by multiplex conventional 
PCR, from the 50 heifers, naturally exposed to Cfv infected bulls 
Culture results Weeks of natural exposure (number of samples) Total 
4 5 6 7 
Positive 15 12 19 12 58 
Negative 35 38 31 38 142 
Total 50 50 50 50 200 
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Table 2.3a. Comparison of Cfv real-time PCR results for bovine vaginal mucus samples, 
prepared with heat lysis protocols (week 6 samples), to results of culture, 
confirmed by multiplex conventional PCR, n=50  
 
C
u
lt
u
re
  
re
su
lt
s 
Sample processing  protocols results (number of samples) 
I II III IV 
P
* 
S
** 
N
*** ∑ P S N ∑ P S N ∑ P S N ∑ 
P 0 5 14 19 4 3 12 19 4 3 12 19 5 3 11 19 
N 3 3 25 31 3 6 22 31 4 0 27 31 3 3 25 31 
∑ 3 8 39 50 7 9 34 50 8 3 39 50 8 6 36 50 
*P-positive; 
**
S-suspicious; 
***
N-negative 
 
Table 2.3b. Comparison of Cfv real-time PCR results for bovine vaginal mucus samples, 
prepared with heat lysis protocols (week 6 samples), to results of culture, 
confirmed by multiplex conventional PCR, after re-running of suspicious 
samples, n=50 
 
C
u
lt
u
re
  
re
su
lt
s 
Sample processing protocols results (number of samples) 
I II III IV 
P
* 
S
** 
N
*** ∑ P S N ∑ P S N ∑ P S N ∑ 
P 0 2 17 19 4 0 15 19 5 2 12 19 5 3 11 19 
N 3 0 28 31 3 1 27 31 4 0 27 31 3 3 25 31 
∑ 3 2 45 50 7 1 42 50 9 2 39 50 8 6 36 50 
*P-positive; 
**
S-suspicious; 
***
N-negative 
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Table 2.4. Comparison of Cfv real-time PCR results for bovine vaginal mucus samples, 
prepared with heat lysis protocols, to results of culture, confirmed by 
multiplex conventional PCR, after called suspicious  samples negative, n=50 
Protocol, result  Culture, result Sensitivity / Specificity 
Positive Negative ∑ 
 
 
I 
Positive 0 3 3 Sens=n/a 
Spec=90.3% (95%CI: 73.9 –96.8%) Negative 19 28 47 
∑ 19 31 50 
II 
Positive 4 3 7 Sens=21.0% (95%CI: 8.1–44.5%) 
Spec=90.3% (95%CI: 73.9 –96.8%) Negative 15 28 43 
∑ 19 31 50 
III 
Positive 5 4 9 Sens=26.3% (95%CI: 11.4–49.8%) 
Spec=87.1% (95%CI: 70.0–95.1%) Negative 14 27 41 
∑ 19 31 50 
 
IV 
Positive 6 4 10 Sens=31.6% (95%CI: 14.9–54.8%) 
Spec=87.1% (95%CI: 70.0–95.1%) Negative 13 27 40 
∑ 19 31 50 
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Table 2.5a. Comparison of Cfv real-time PCR results for bovine vaginal mucus samples, 
prepared with different protocols, to results of culture, confirmed by multiplex 
conventional PCR, n=200 
 
Culture  
results 
Sample processing protocols results (number of samples) 
III IV MagMAX 
P
* 
S
** 
N
*** ∑ P S N ∑ P S N ∑ 
P 17 7 34 58 16 8 34 58 21 16 21 58 
N 22 12 108 142 15 23 104 142 21 25 96 142 
∑ 39 19 142 200 31 31 138 200 42 41 117 200 
*P-positive; 
**
S-suspicious; 
***
N-negative 
 
Table 2.5b. Comparison of Cfv real-time PCR results for bovine vaginal mucus samples, 
prepared with different protocols, to results of culture, confirmed by multiplex 
conventional PCR, after the re-running of suspicious samples, n=200 
 
Culture  
results 
Sample processing protocols results (number of samples) 
III IV V 
P
* 
S
** 
N
*** ∑ P S N ∑ P S N ∑ 
P 20 2 36 58 17 1 40 58 28 3 27 58 
N 26 5 111 142 16 2 124 142 29 2 111 142 
∑ 46 7 147 200 33 3 164 200 57 5 138 200 
*P-positive; 
**
S-suspicious; 
***
N-negative 
 
 
  
77 
 
Table 2.6. Comparison of Cfv real-time PCR results for bovine vaginal mucus samples, 
prepared with different protocols, to results of culture, confirmed by multiplex 
conventional PCR, after called suspicious  samples negative, n=200 
Protocols, results  Culture, results Sensitivity / Specificity 
Positive Negative ∑ 
 
 
III 
Positive 20 26 46 Sens=35.0% (95%CI: 24.2%–48.0%)  
Spec=81.1% (95%CI: 72.7%–87.3%) Negative 38 116 154 
∑ 58 142 200 
IV 
Positive 17 16 33 Sens=29.4% (95%CI: 19.6%–41.6%) 
Spec=88.2% (95%CI: 82.1%–92.4%) Negative 41 126 167 
∑ 58 142 200 
V 
Positive 28 29 57 Sens=48.4% (95%CI: 36.9%–60.1%) 
Spec=78.9% (95%CI: 71.4%–84.8%) Negative 30 113 143 
∑ 58 142 200 
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3. EFFICACY OF A COMMERCIAL VACCINE FOR BOVINE GENITAL 
CAMPYLOBACTERIOSIS IN PREVENTING INFECTION AND REPRODUCTIVE LOSS IN 
CATTLE 
In chapter 2 Cfv real-time PCR results for samples, prepared using heat lysis and magnetic 
bead based sample preparation techniques, were compared to results of direct, selective culture 
of bovine vaginal mucus. The heat lysis sample preparation protocol, previously utilized for 
bovine preputial samples (Chaban et al. 2012. Can J of Vet Res; 76:166), did not demonstrate 
satisfactory performance for vaginal mucus and required some modifications. Modified heat 
lysis protocols were compared to culture, confirmed by multiplex conventional PCR, and to 
results of real-time PCR samples, prepared with a commercial magnetic bead-based extraction 
kit. Release of DNA directly from a CVM sample by a modified heat lysis protocol was easy to 
perform but demonstrated low sensitivity and could be performed as a rapid screening 
approach for BGC after validating on fresh samples. The magnetic bead-based extraction 
protocol demonstrated slightly higher sensitivity but was time and resource consuming to 
perform. The biggest number of positive samples was detected with selective culture of bovine 
vaginal mucus, when colonies, consistent with C. fetus morphology, were subjected to 
conventional PCR using MG3F/MG4R and VenSF/VenSR primers. This method was chosen 
for testing vaginal mucus samples in the vaccine trial, described in chapter 3.        
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3.1. ABSTRACT 
Introduction — Bovine Genital Campylobacteriosis occurs worldwide causing early pregnancy 
loss and temporary infertility. While commercial vaccines are available, their effectiveness has 
not been well documented in the peer-reviewed literature. 
Objective —  To compare the risk of infection and reproductive failure in heifers, exposed to 
BGC through natural breeding, that were vaccinated with a multivalent commercial vaccine 
containing C. fetus antigen, to heifers vaccinated with a comparable product without C. fetus. 
Study design — Prospective randomized controlled clinical trial 
Animals — 50 cross-bred beef heifers  
Materials and methods — Heifers were randomized to treatment and control groups and then 
exposed to bulls, infected with BGC. The animals in the control group were vaccinated with a 
commercial vaccine against Infectious Bovine Rhinotracheitis virus, BVD, Parainfluenza-3, 
Respiratory Syncytial Virus, and Leptospira interrogans. The treatment group was vaccinated 
with a similar product also containing the C. fetus antigen. Vaginal mucus samples were 
collected and cultured for 16 weeks; tiny translucent colonies were Gram-stained and if 
consistent with C. fetus morphology were subjected to conventional PCR using MG3F/MG4R 
primers targeting carbon starvation gene protein in both C. fetus subspecies and VenSF/VenSR 
primers targeting parA gene fragment in C. fetus spp. venerealis. Pregnancy status was 
determined by trans-rectal ultrasonography and concentration of pregnancy-specific protein B in 
serum. Serum neutralizing antibody titers to C. fetus were also measured.  
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Results —There was no significant difference between groups either in risk of isolating Cfv 
(P>0.17) or in the proportion of heifers that cultured positive at least once (P=0.42). Similarly, 
there was no difference in the median number of times that heifers cultured positive for Cfv from 
vaginal mucus samples (P=0.24) and the rate at which heifers from control and treatment groups 
first cultured positive (P=0.67). The proportion of heifers that were pregnant each week during 
the study did not differ by treatment group, based on either ultrasound (P>0.31) or serum PSPB 
(P>0.31). The time to first  pregnancy detected by ultrasonography did not differ between 
treatment and control groups for heifers ever diagnosed as pregnant (P=0.30) and those that 
remained pregnant at the end of the study (P=0.70). There was no significant difference in the 
proportion of animals, ever diagnosed pregnant during the study, by treatment group (Tx=48%, 
C=36%; P=0.39) and in pregnancy loss rates (Tx=75.0%, C=67%; P=0.28). However, heifers 
that aborted during the study were 4 times more likely to be culture positive for BGC than those 
that did not abort (P=0.01). Heifers in the treatment group that were not pregnant at the end of 
the study cultured positive 1.5 times more often than pregnant animals  (P=0.04); nonpregnant 
heifers from control group were 4 times more likely to culture positive (P=0.01). There was no 
difference in the number times cultured positive in heifers that were not pregnant at the end of 
the study (P=0.14). Neither the maximum detected MAT antibody titers (P=0.57) to C. fetus nor 
the proportion of positive MAT titers (P=0.99) differed by treatment. However, the mean ELISA 
antibody to C. fetus concentrations after vaccination were more than 2 times higher in the 
treatment group than in the control group (P<0.02).  
Conclusions — Vaccinating heifers with a multivalent commercial vaccine, containing C. fetus 
antigen, according to the label directions did not significantly reduce infection rates or improve 
pregnancy when challenged with exposure to bulls, infected with BGC.       
86 
 
3.2. INTRODUCTION 
Bovine Genital Campylobacteriosis (BGC) is a venereal disease characterized by early 
pregnancy loss and temporary infertility [1,2]. It is caused by the bacteria Campylobacter fetus 
subspecies venerealis (Cfv). BGC occurs worldwide, wherever natural service is used for 
breeding [3–8]. Pregnancy loss is often not detected until pregnancy examination or a high 
number of females are noticed exhibiting estrus after the breeding season [9]. Economic losses 
associated with acute outbreaks of Cfv in susceptible herds and chronic infections can be severe 
[1,4]. BGC is maintained and transmitted by carrier bulls [9]. Infection of a susceptible cow or 
heifer during breeding results in endometrial inflammatory changes and potentially in death and 
resorption of the conceptus [1,10].  
The advent and use of artificial insemination, testing and vaccination has decreased the 
occurrence of BGC in many countries [8,10]. However, the beef industry, unlike dairy business, 
primarily uses natural breeding [11, 12]. Systemic immunization could prevent or eliminate Cfv 
infection by inducing IgG antibodies in genital secretions and serum, shortening infection and 
reducing reproductive losses. Vaccine-induced immunity has been reported to be effective but 
short-lived and advised that vaccination be boosted bi-annually to ensure adequate herd 
protection [11].   
 The relatively small number of peer-reviewed reports to date evaluating the effectiveness of 
vaccination of bulls [11, 13–17, 18, 19], cows and heifers [16, 19–25, 26–28] were summarized 
in the Table 3.1. Both monovalent [11, 13–21, 23, 25–28] and polyvalent [22, 24] vaccines have 
been used for vaccination against BGC in heifers. Only a small number of studies have reported 
commercial vaccines [11, 16, 18, 21, 22, 24, 26]. The remainders were prepared from local 
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strains [13–16, 20, 22–25, 27, 28] utilizing oil [13, 15, 16, 20, 23, 24, 27, 28] or aluminum 
compounds adjuvants [22]. Incomplete Freund’s adjuvants have also been used [14, 25]. Usually 
systemic vaccination for BGC was described in vaccine trials [11, 13–17, 19–25, 26–28], except 
in one study mucosal vaccination was perform as an addition to systemic vaccination [24]. 
Animals were challenged by natural exposure to infected animals of opposite sex [14–16, 19, 20, 
22, 26], intra-vaginal [21, 23, 25] or intra-preputial [11] Cfv culture infusion, or both natural 
exposure and culture infusion [17, 24, 27, 28].      
Vaccination for BGC with monovalent vaccine has been reported as effective method of 
preventing infection and associated reproductive losses; however, most  of the studies are more 
than 30 years old, performed on experimental [13, 14, 19, 20, 23, 25, 27, 28] and commercial 
vaccines [11, 17, 19, 21, 26]. Nearly half of early published studies about monovalent 
experimental vaccines were neither contained information about randomization of animals to 
treatment groups nor statistically conclusive [13, 14, 16, 23, 25]. For instance, vaccination of 188 
bulls with vaccine, prepared with local antigen, resulted in their non-infected status after natural 
exposure in infected areas for 1 year [14]. Another trial reported successful vaccination of 46 
heifers and 4 bulls [16]. However, there was no information found in these papers about the 
method how treatment groups were formed and only percentages were reported in these trials 
without appropriate data analysis.    
Studies of monovalent commercial vaccines in most cases were randomized [11, 17, 18, 26] and 
reported statistically analyzed data [17, 18, 21, 26]. Study of monovalent commercial vaccine, 
prepared from an Australian isolate of Campylobacter fetus subspecies venerealis biovar 
intermedius (Cfvi), demonstrated 7 times less infection in the group of vaccinated heifers, 
compare to non-vaccinated [21]. This study reported statistically significant data, but nothing 
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was mentioned how treatment and control groups were formed. Randomized and statistically 
conclusive study of monovalent commercial vaccine was performed on 12 infected bulls and 
reported increasing in serum antibodies to C. fetus titers in vaccinated bulls, and when exposed 
afterwards to virgin heifers resulted in non-infection status of bulls and heifers [17].    
There have been reports of utilizing monovalent vaccine with a purpose to cure BGC infection 
[14, 15, 23, 25]. One study suggested that active systemic immunization would be able to 
eliminate vaginal career state in heifers [25]. Later, Cfv bacterin in oil adjuvant was tested, but 
recommended as an additional strategy only [15].                
The effectiveness of commercial polyvalent vaccines has not been as clearly described. There 
have been two peer-reviewed, recent studies [22, 24] that were well designed clinical trials with 
appropriate data analyses. g. In one study, polyvalent commercial vaccine, formulated with 
inactivated antigens of Leptospira interrogans serovar pomona, Haemophilus somnus, C. fetus 
subsp. venerealis, C. fetus subsp. fetus and viruses of the infectious bovine rinotracheitis and 
bovine viral diarrhoea in aluminium hydroxide adjuvant, was used to vaccinate heifers that were 
consequently naturally challenged for 60 days [22]. Vaccinated and control heifers had poor 
reproductive performance and did not demonstrate significant systemic antibody level, detected 
by immunofluorescent antibody test (IFAT) [22].  
When commercial and experimental dual vaccines containing Tritrichomonas foetus and 
Campylobacter fetus antigens were tested, vaccinated heifers resisted or quickly cleared both 
pathogens, had a higher pregnancy rate, and a higher systemic immune response. The 
experimental vaccine, containing antigens from local strains of C. fetus and T. foetus, given both 
subcutaneously and intravaginaly, was superior to the commercial vaccine [24]. Whether that 
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was due to the fact of using local strains of the pathogens in experimental vaccine or due to local 
application of that preparation remained questionable.    
It could be suggested  from the literature review that monovalent vaccines demonstrated better 
effectiveness than polyvalent; however, most studies on monovalent vaccines were done quite 
long time ago and about half of these trials either contained no information regarding 
randomization [15, 21] or data that was not analyzed appropriately [11], or both [13, 14, 16, 23, 
25]. The majority of such studies were performed on vaccines, prepared from the antigens of 
local strains of C. fetus [13, 15, 16, 20, 23, 24, 25], sometimes combining systemic and local 
routes of vaccination [24], which could be another reason of their improved effectiveness. There 
a few reports proportedly demonstrating successful use of commercial monovalent vaccines [11, 
17, 21]. However, trials with commercial monovalent vaccines were performed on limited 
number of animals (12–33) resulting in a small sample size [11, 17, 18, 21, 26], while the 
number range of animals used in the studies with experimental monovalent vaccines was 4–321 
[13, 15, 16, 20, 23, 24, 25]. However, studies of commercial vaccines in most cases were 
randomized and statistically conclusive [18, 19, 26].  
Currently, commercial vaccines are more convenient and less expensive to use for producers 
than those, exclusively prepared for every single farm or area, based on local strains of 
pathogens (autogenous). Preparation of autogenous vaccines is not really practical, especially 
when considering withdrawal times and food safety. When comparing monovalent and 
polyvalent vaccines, the latter are preferable to use in modern farms and ranches, since one 
vaccination against many pathogen is less stressful for animals and personnel than multiple 
injections.  There was only one peer-reviewed study in the last decade [22] concerning 
polyvalent vaccine for BGC. This vaccine contained Leptospira innterrogans serovar pomona, 
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Haemophilus somnus, Cff and viruses of infectious bovine rinotracheitis and bovine viral 
diarrhoea in addition to Cfv.  Since a small number of animals were used in that trial, the 
efficacy of such vaccination as reported was questionable [22]. Therefore, there is a need to 
better understand the efficacy of commercially available Cfv vaccines so that veterinarians can 
be informed and make effective decisions on vaccination practices for herds. Well-designed 
clinical trials with commercially available polyvalent vaccine containing C. fetus antigen, 
followed by data analysis with updated statistical techniques would be appropriate.     
 The overall purpose of this project was to describe the differences in infection rate and 
reproductive performance between two groups of heifers naturally exposed to Cfv-infected bulls. 
The first group was vaccinated with polyvalent vaccine containing C. fetus antigen and the 
second was vaccinated with similar polyvalent vaccine that did not contain C. fetus antigen. The 
primary objectives were to compare the percentage of heifers that became infected with Cfv, the 
proportion of heifers that became pregnant, and the difference in days to pregnancy between the 
the two groups. A secondary objective was to describe and compare serum concentrations of 
C.fetus antibodies between the two treatment groups.  
3.3. MATERIALS AND METHODS 
3.3.1. Animals and treatments 
All animal procedures were performed in accordance with the Canadian Council of Animal Care 
and approved by the University of Saskatchewan Animal Research Ethics Board (Protocols 
#20100061 and #20100077). A sample size of 25 heifers per treatment group was calculated 
based upon an expected pregnancy proportion of 30% and 75% in the control and treatment 
groups, respectively, with 80% power and 95% confidence. [29].  
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Fifty cross-bred beef heifers were housed during May and June 2013 in a 35m x 35m drylot pen 
at the university research farm
a
. The heifers were fed a diet of mixed hay, barley silage and 
mineral supplement according to NRC requirements. Each heifer was examined trans-rectally via 
ultrasonography using a commercial scanning device
b
 with 5.0 MHz 10 cm linear probe for the 
presence of a corpus luteum as evidence of cyclicity (Weeks -4 and 0) (Table 3.1). Heifers were 
paired by body weight into 25 replicates. Animals within each replicate were then randomized by 
coin toss to 1 of 2 vaccination treatments where “heads” would mean BGC vaccination and 
“tails” would mean control vaccination.  
The control group (C) was vaccinated with 2 doses (2 ml/dose) of a commercial vaccine
c
, 
containing the following antigens: Bovine Rhinotracheitis, Bovine Virus Diarrhea, 
Parainfluenza-3, Respiratory Syncytial Virus, Leptospira interrogans (serovars canicola, 
grippotyphosa, hardjo, icterohaemorrhagiae, pomona) with a proprietary adjuvant, 
subcutaneously 7 and 4 weeks before breeding. The treatment group (Tx) got 2 doses (2 ml/dose) 
of the commercial vaccine
d
, containing the same components as for control plus the 
Campylobacter fetus antigen, subcutaneously 7 and 4 weeks before breeding.  
Heifers were exposed to 2 of 3 Cfv-infected Black Angus bulls that were genetically distinct 
from the heifers for a period of 63 days (July 07–September 02, 2013). While heifers were only 
exposed to two of the bulls at a time, a third bull was kept as spare and used in case of injury or 
disease. The bulls were vaccinated with the same vaccine
c
 as heifers from the control group and 
with the vaccine
e
 for Fusobacterium necrophorum. During the breeding period, the heifers and 
bulls were rotationally grazed on four 12-acre pastures.  
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A chin-ball marker
f
 was placed on each of the bulls to monitor the heifer’s exposure to the bulls. 
A different paint color was used for each bull. Heatmount detectors
g
 were also placed on the tail 
head of each heifer at the beginning of the trial (day 0) to identify heifers in estrus. The 
Heatmount detector and chin-ball paint were monitored visually and recorded once daily (for 30–
60 minutes each morning) during the first 3 weeks of the trial to monitor bull exposure.  
3.3.2. Data and sample collection 
The heifers and bulls were walked into corrals, adjacent to the pastures, and then moved through 
a handling facility to facilitate sample collection. During the procedures, animals were restrained 
in a manual squeeze chute and haltered for blood collection. A summary of the vaccination, data 
and sample collection schedule is provided in Table 3.2. 
Preputial scrape sampling 
Preputial scrape samples were collected from the 3 bulls weekly from week 0 to 10 for culture 
and real-time PCR to monitor their Cfv infection status. Bulls were sampled using a previously 
described aspiration technique [30]. Cryovials with samples were transported back to the lab in a 
styrofoam box with warm water bags within 2h of collection, maintaining environmental 
temperature at approximately 25
o
C. 
Vaginal mucus sampling 
Two vaginal mucus samples were collected before bull exposure to ensure that the heifers were 
free from Cfv infection before beginning the trial. Heifers were then sampled weekly from weeks 
1 to 10 of exposure. Mucus samples were also collected at weeks 12, 14 and 16 (Table 3.2).  
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Sampling was performed by aspiration using a 25” pipetteh, connected to a 20-ml syringe. Prior 
to aspiration, approximately 2 ml of phosphate buffered saline (PBS) was passed through the 
pipette into the syringe. The pipette was then placed inside a solid 12-inch plastic AI sheath 
protector
i
. The tail of each heifer was held and perineum washed with soapy warm water. The 
labia were then opened and the pipette inserted into the vagina while protected in the AI sheath. 
The pipette was then advanced through the AI sheath. The PBS in the syringe was then expelled 
and 15 mL of suction applied. The syringe was then maneuvered cranial and caudal moving the 
pipette along the vaginal walls approximately 10 times while maintaining suction. Finally, the 
pipette was pulled caudally into the AI sheath before removing it from the vagina to minimize 
fecal contamination. Once the aspiration of mucus was complete, the pipette was withdrawn and 
rinsed into a 4-ml cryovial tube containing 2 ml of PBS. Cryovials were transported back to the 
lab in a styrofoam box with warm water bags within 2h of collection, maintaining environmental 
temperature at approximately 25
o
C.  
Blood sample collection 
Two 10-ml blood samples were collected from the jugular vein into red-topped vacuum tubes
j
 on 
weeks -7, 0, 2 through 8, 10 and 16. The blood samples were kept at room temperature until 
transported back to laboratory. In laboratory the blood was centrifuged at 1,500 g for 15 minutes. 
The serum was then aliquoted into three 2.5 mL cryovials and then frozen at -20
o
C until samples 
collection was complete. 
Trans-rectal ultrasonography for pregnancy 
The heifers were examined by trans-rectal ultrasonography every Monday from weeks 4 to 16 of 
the study. Pregnancies were approximately aged via ultrasonography by taking into account the 
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size of the vesicle, fetus and cotyledons. The heartbeat of the embryo was assessed to confirm 
viability.  
Breeding soundness examination 
Each of the 3 bulls had a breeding soundness exam on weeks -4 and 11 where they were assessed 
for physical soundness, scrotal circumference, sperm motility and morphology according to 
Barth (2013) [31]. 
3.3.3. Laboratory testing: 
Culture of vaginal mucus and preputial samples, confirmed by multiplex conventional PCR 
Upon arrival at the lab, an aliquot of 300 μl was taken from the cryovial and spread onto a 0.65-
µm mixed cellulose ester membrane filter
k
, placed on 5% blood agar plates and incubated at 
37°C under microaerobic conditions with an integrated chemical packs
l
 for rapid carbon dioxide 
(CO2) generation [32]. Plates were examined after 72h of incubation and colonies, consistent 
with Campylobacter fetus morphology, were Gram stained. Plates that contained no evidence of 
Campylobacter colonies were incubated for an additional 72h. Colonies were not counted, but  
those with Gram stain results, consistent in morphology with Campylobacter, were subjected to a 
conventional multiplex PCR [33], using the primers MG3F/MG4R and VenSF/VenSR, as 
previously described [30, 32, 33], to determine the species and subspecies.   
Pregnancy-specific protein B (PSPB) 
The concentration of pregnancy-specific protein B (PSPB) in the serum was measured using a 
commercial kit
m
 at a commercial laboratory
n
. Sera were frozen and tested together at one time at 
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the end of the trial to minimize variation. The testing was performed utilizing the “sandwich” 
enzyme-linked immunosorbent assay (ELISA) [34]. Accordingly to the kit manual
m
 the most 
accurate results are received when the test is performed after 28 days post-breeding, giving 
greater than 99 percent of accuracy when an animal is categorized as open.  
Standards of known PSPB concentrations were run with each assay to determine the optical 
density (OD) values for assigning pregnant/not pregnant ranges, the “cut off point” was 0.15 
(Table 3.3).  
Antibodies to C. fetus 
Serum neutralizing antibody titers to C. fetus were measured in this study with microscopic 
agglutination test (MAT) and ELISA by a commercial laboratory
p
. ELISA was performed as 
previously described for quantification of IgG antibodies against C. fetus after vaccination [35].   
For the MAT test sera were twofold serially diluted in U-bottom microtiter plates (50 µl per 
well). The diluent was phosphate buffered saline (PBS) containing 0.1% gelatin. Fifty µl of C. 
fetus inactivated antigen (0.2% formalized, 54–58 %T at 550 nm) was added to each well and the 
plates were incubated at 37°C for 16–24 hours. The plates were held an additional 16–24 hours 
at 15–30°C before final reading.  
A positive reaction in MAT was defined in case when a smooth mat of cells covered the entire 
bottom of the well with no defined button of un-reacted antigen. A negative reaction ranged from 
a partial smooth mat to a compact button of unreacted antigen. The titer was expressed as the 
highest serum dilution causing a positive reaction. MAT titers 64 and above were considered as 
positive.  
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3.3.4. Data analyses 
All data were entered into a spreadsheet before analysis, and appropriate descriptive statistics 
were reported for each variable, using commercial statistical software
p
. The 95% confidence 
intervals (95% CI) were reported for means and proportions, while inter-quartile ranges (IQR) 
were reported for medians.  
Heat detection and bull exposure  
The proportions of heifers in estrus and mounted by bulls were compared between treatment 
groups, using Fisher’s exact test, during the periods when these events happened the most. The 
results were reported as odd ratios (OR) with 95% confidence intervals (95% CI) [29, 36]. The 
median numbers of days from the start of the study to the first estrus and to the first mounting by 
bulls were also compared across treatment groups using Wilcoxon rank sum test [29].        
Generalized Estimating Equations (GEE) with a logit link function, binomial distribution and 
AR(1) correlation was used to compare differences in the probability a heifer was exposed to a 
bull among the 2 bulls used in the study and the 2 treatment groups for the first 12 days and 
again for days 14 to 21, while accounting for repeated measures from individual heifers. Firstly, 
treatment groups, bulls, day number were used as independent variables, followed by post-
estimation as margins of bulls variables; descriptive statistics and comparison of heifers exposure 
to different bulls were reported. Secondly, treatment groups, bulls, day number, and 
treatment/bull interaction were used as independent variables, followed by post-estimation as 
margins and pair-wise comparison of the interaction term that were reported as descriptive 
statistics and comparisons between exposure of every bull to different treatment groups of 
heifers [37]. The results were reported as OR with 95% CI [29].  
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Culture of vaginal samples, confirmed by multiplex conventional PCR  
A GEE model with a logit link function, binomial distribution and AR(1) correlation was used to 
compare the proportion of vaginal mucus samples, cultured positive weekly over the period of 
the study, between treatment and control heifers by treatment, time, and the interaction of these 
two terms while accounting for repeated measures from individual heifers. Pair-wise comparison 
between treatment groups by week of study were reported for the interaction terms [37]. The 
results were reported as OR with 95% CI [29].   
The proportion of heifers that had at least 1 positive vaginal mucus culture was compared by 
treatment and by exposure of heifers to different bulls using Fisher’s exact test. The results were 
reported as OR with 95% CI [29]. 
The median number of times that heifers cultured positive during the study was compared by 
treatment with Wilcoxon rank sum test. The median number of times that heifers cultured 
positive at least once was compared between heifers, mounted by three different bulls, using 
Kruskal-Wallis one-way non-parametric analysis of variance (ANOVA). The time from the start 
of exposure to when first cultured positive for Cfv was compared by treatment with Wilcoxon 
rank sum test [29].  
Pregnancy diagnosis by serum PSPB and ultrasonography  
Cohen’s kappa coefficient was calculated in order to measure the agreement between the 
pregnancy results, obtained by serum PSPB and ultrasonography [29]. Abortion events were 
estimated looking at the spreadsheet with weekly pregnancy detection data.   
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GEE models, using a logit link function, binomial distribution and AR(1) correlation, were used 
to compare the  proportion of heifers, detected pregnant each week by ultrasound and then PSPB, 
between treatment groups in a model including study week and the interaction between treatment 
group and week while accounting for repeated measures from individual heifers. Pair-wise 
comparisons were reported between treatment groups by week of study [37]. The results were 
reported as OR with 95% CI [29]. 
Using the estimated fetal age from ultrasonography, the days from initial bull exposure to 
pregnancy was estimated for all heifers, diagnosed pregnant at least once during the study, and 
also for animals that remained pregnant at the end of the trial. Only days to initial pregnancy 
diagnosis was included in this analysis. That is, if heifers were pregnant, aborted and then 
became pregnant again, we only considered the first pregnancy.   
Fisher’s exact test was used to compare the risk between treatment groups that heifers were 
diagnosed pregnant at least once during the study, pregnant at the end of the study, aborted, and 
that either heifers that aborted or heifers than had not aborted were cultured positive at least once 
during the study [29]. The results were reported as OR with 95% CI [29]. 
Wilcoxon rank sum test was then fit to compare the median number days from the start of 
exposure to first pregnancy between treatment groups for all pregnant during the study heifers, 
those that remained pregnant at the end of the trial, and pregnant heifers that never aborted, as 
well as the heifers that aborted during the study and those that did not abort in the number of 
times cultured positive. Differences in the number of times cultured positive were also compared 
with Wilcoxon rank sum test between pregnant and non-pregnant heifers at the end of the study 
overall and by treatment group [29].  
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C. fetus antibody titer serology  
Fisher’s exact test was used to compare the proportion of positive titers, detected by MAT, 
during the study by treatment groups. The results were reported as OR with 95% CI [29]. The 
number of Cfv positive titers for each heifer and the maximum serum titre for C. fetus was 
compared between vaccine groups, using a Wilcoxon rank sum test [29].  
A GEE model of log base 10 transformed ELISA results assuming a normal distribution, linear 
link function and AR(1)  correlation was used to compare the mean of value of titers, detected by 
ELISA, between treatment and control heifers at each collection period during the study while 
accounting for repeated measures from individual heifers. The margins and pair-wise comparison 
of the interaction term were performed as model post-estimations and were reported as 
descriptive statistics after exponentiation and comparisons between treatment groups by the time 
of titers measuring. The same model and the similar actions were performed to compare the 
mean of value of titers, detected by ELISA after exposure, between heifers aborted during the 
study and those that did not [37].  
 All models were assessed for outliers and goodness of fit. Differences were considered 
statistically significant when P<0.05 [29].  
3.4. RESULTS 
3.4.1. Heat detection and bull exposure results 
Observation of the Heatmount detectors suggested that all heifers expressed estrus during the 
first 12 days of bull exposure, 38 out of 50 heifers expressed estrus during the first 7 days and 
there was no difference between the treatment groups (Treatment (Tx)=19/25 (76%), Control 
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(C)=19/25 (76%); OR=1.00, 95% CI: 0.22–4.50; P=0.99). Observations of chin-ball markers 
suggested that all heifers were mounted by bulls at least once during the first 17 days of 
exposure, 46 out of 50 heifers were mounted in the first 12 days of exposure and there was no 
significant difference by treatment (Tx=22/25 (88%), C=24/25 (96%); OR=0.31, 95% CI: 0.01–
4.22; P=0.61).  
There was also no difference by treatment groups in the median number of days from the 
beginning of the study to when heifers expressed the first estrus (C=5, IQR: 2–7, Tx=4, IQR: 2–
6; P=0.48). Similarly, the difference was not detected in median number of days from the 
beginning of the study to when heifers were mounted by bulls for the first time (Tx=6, IQR: 4–8, 
C=6, IQR: 2–8; P=0.35). 
Three bulls, known to be infected with BGC, were used in this study: “19U”, “953” and “TD” 
(Table 3.4). Initially, “19U” and “953” were exposed to the heifers; however, bull “953” 
developed a toe abscess, was removed on day 13 and replaced by “TD”. During the study 44/50 
(88%) of heifers were exposed to bull “19U”, 42/50 (84%) – to bull “953”, and 34/50 (68%) – to 
bull “TD”. Overall, 45/50 (90%) of heifers were mounted by more than one bull during the 
exposure and only 5 heifers were exposed to just one bull during the study (one to bull “19U”, 
four to “953”, and none to “TD”).  
Based on observations of chin-ball markers in the first 12 days of exposure, bull “19U” 
demonstrated less breeding activity than “953” (“19U”=11%, “953”=23%; OR=0.38, 95% CI: 
0.29–0.52; P<0.001), but there was no difference between bulls, detected during days 13–21, 
when “19U” was compared to “TD” (“19U”=19%, “TD”=21%; OR=0.85, 95% CI: 0.65–1.13; 
P=0.26).  However, every bull in this study demonstrated similar exposure in the treatment and 
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control groups both on days 1–12 (“19U”: Tx=11%, C=10%, OR=1.11, 95% CI: 0.65–1.91, 
P=0.69; “953”: Tx=21%, C=24%, OR=0.86, 95% CI: 0.57–1.29, P=0.47) and on days 13–21 
(“19U”: Tx=17%, C=20%, OR=0.85, 95% CI: 0.49–1.47; P=0.56; “TD”: Tx=23%, C=19%, 
OR=1.27, 95% CI: 0.75–2.16; P=0.37) of this study.   
3.4.2. Results of preputial samples culture, confirmed by conventional PCR 
Table 3.4 summarized the preputial culture results of the 3 bulls and the time period, each bull 
was exposed to the heifers. From 9 weeks before exposure to the heifers, all 3 bulls showed 
variable Cfv status, based on weekly culture and real-time PCR of preputial samples. Preputial 
samples of the bulls collected in 2, 4, 17 and 21 weeks after exposure confirmed that bull “19U” 
continued to be positive after the study.  
Bull “19U” was treated for foot rot in week 1, but was sound within 2 days of application of a 
topical oxytetracycline foot bandage. This bull was confirmed as cultured positive on all 5 tests 
prior to heifer exposure and 3 after the start of heifer exposure. Bull “953” was replaced by “TD” 
in week 2. Despite remaining “physically sound” bull “TD” had culture and real-time PCR 
negative results for all but 1 test during the heifer exposure.  
Overall, 21/39 (54%) of preputial samples collected from the bulls during the study were 
cultured negative. The bulls were tested once two weeks after breeding and smegma samples 
results were culture and real-time PCR negative. The bulls were subsequently retested on three 
occasions over the next 5 months with no further breeding exposure, and only one of them 
(“19U”) had culture and PCR positive results (Table 3.4). All three bulls were classified as 
satisfactory based on breeding soundness examinations before and after exposure to the heifers. 
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Bull ‘19U’ was retained at the research farm and demonstrated culture and real-time PCR 
positive results in the spring of 2014. 
3.4.3. Results of vaginal mucus culture, confirmed by conventional PCR 
The first culture-positive vaginal mucus samples were found two weeks after the start of bull 
exposure. The proportion of heifers in each treatment group with Cfv, isolated from their vaginal 
mucus, is summarized by week in Figure 1. There was no significant difference in the isolation 
of Cfv from vaginal mucous in the treatment and control groups in weeks 2 to 7, 9, 10, 12, 14, 
and 16 (P>0.17). The only significant difference between treatment groups was in week 8 
(Tx=1/25 (4%); C=7/25 (28%); OR=0.11, 95% CI: 0.01–0.99; P=0.04) (Supl. Table 3.1).  
During the study, 43 out of 50 heifers (86%) had at least one vaginal mucus sample, cultured 
positive for Cfv. There was no significant difference in risk of having at least 1 positive vaginal 
mucus culture between treatment groups (Tx=23/25 (92%); C=20/25 (80%); OR=2.87, 95% CI: 
0.41–32.7; P=0.42) and between heifers, mounted by different bulls (“19U”=38/44 (86%); 
“953”=35/42 (83%); “TD”=31/34 (91%); P=63). Five of the 43 heifers (12%) cultured positive 
only once during the study period. There were five heifers that were mounted only by one bull 
during the study, based on observations of chin-ball markers and all of them were cultured 
positive for Cfv 2–7 times.    
There was no difference in the median number times that heifers cultured positive for Cfv from 
vaginal mucus samples within each treatment group (C=3, IQR: 1–5; Tx=2, IQR: 2–3; P=0.24) 
and between heifers mounted by different bulls (“19U”=2, IQR: 1.5–4; 953=2, IQR: 1–4; 
“TD”=2, IQR: 1–4; P=0.95). There was also no significant difference in the median number days 
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from the start of exposure to when treatment and control heifers were first time cultured positive 
for Cfv from vaginal mucus (C=35, IQR: 21–42; Tx=28, IQR: 21–35; P=0.67). 
3.4.4. Pregnancy diagnosis by serum PSPB and ultrasonography 
The proportion of heifers, diagnosed pregnant by ultrasound and serum PSPB, by week and 
treatment group are summarized in Figures 3.2a and 3.2b. There was good agreement 
(kappa=0.840, 95% CI: 0.839–0.841) between the two methods of detecting pregnancy. The first 
increase in serum level of PSPB above cut-off point (Table 3.3) was detected in week 4 of 
exposure and first pregnancy was detected by ultrasound in week 5.  
The earliest pregnancy, diagnosed by ultrasound, was 25 days. We were able to estimate 
pregnancy term, detected by PSPB by comparing to ultrasound results of the same or consequent 
week in 14 out of 21 heifers, diagnosed pregnant during the study (1/14 was estimated 12 days; 
5/14: 23–25 days; 8/14: 26–32 days). Therefore, the earliest pregnancy, detected by increased 
serum level of PSPB and estimated by comparing to subsequent results of ultrasound was 12 
days.  
The proportion of heifers, diagnosed pregnant by serum level of PSPB, did not differ  between 
treatment and control groups for any week during the study (P>0.31) (Figure 2a, Supl.Table 
3.2a). Similar findings were noted when the pregnancy was detected by serum ultrasound 
(P>0.31) (Figure 2b, Supl.Table 3.2b).  
During the study 21/50 (42%) of heifers were detected pregnant at least once and there was no 
signficant difference between treatment groups (Tx=12/25 (48%); C=9/25 (36%); OR=1.64, 95% 
CI: 0.46–5.94; P=0.57). There was no difference between the treatment and control groups in the 
median number days to first pregnancy either in all heifers, detected pregnant during the study 
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(C=47, IQR: 17–52; Tx=19, IQR: 10–38; P=0.30) or in those that remained pregnant at the end 
of the study (C=17, IQR: 9–35; Tx=16, IQR: 7–40; P=0.70) and animals that never aborted, 
maintaining active pregnancy (C=17, IQR: 2–54; Tx=40, IQR: 7–52; P=0.83), based on 
ultrasonography.  
Fifteen of 21 pregnant heifers lost their pregnancy (71%), but 6 of the 15 heifers, who lost their 
pregnancy, became pregnant again by the end of the study. Therefore, 6 out of 12 pregnant at the 
end heifers (50%) aborted earlier and other six maintained active pregnancy (three in each 
treatment group). We estimated that 42% of abortions happened before day 25 of gestation, 47% 
between days 25–35, and 11% in days 45–55 of pregnancy. Every heifer, aborted during the 
study, aborted only once accordingly to the data from our weekly pregnancy checking. There 
was no significant difference in pregnancy loss rates by treatment group (Tx=75%; C=67%; 
OR=1.48, 95% CI: 0.76–2.87; P=0.28). However, aborted animals had more frequent positive 
vaginal mucous culture results (median=2, IQR: 2–4) than heifers that did not abort 
(median=0.5, IQR: 0–1) (P=0.01).  
Overall, 12 heifers were pregnant at the end of the study: 5 were from the control group and 7 
from the treatment group. The 12 pregnant heifers at the end had less frequent cultured positive 
results for Cfv in vaginal mucus (median 1.5, IQR: 0.5–2) as compared to the 38 non-pregnant 
heifers (median 3, IQR: 2–4) (P=0.002). The 5 heifers, pregnant at the end of the study, in the 
control group cultured positive a median of 1 time (IQR: 0–2), compare to 4 times for 20 non-
pregnant heifers in this group (IQR: 2–6) (P=0.04). The 7 heifers from treatment group, who 
were pregnant at the end, were cultured positive a median of 2 times (IQR: 1–2), compare to 3 
times for 18 non-pregnant heifers from the same group (IQR: 2–3) (P=0.01). However, there was 
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no difference between treatment groups in number of culture positive samples in non-pregnant 
heifers at the end of the study (C: median=4, IQR: 2–6; Tx: median=3, IQR: 2–3; P=0.14). 
3.4.5. C. fetus antibody titer serology 
All blood samples, collected from the heifers 7 weeks before and in week 0 of exposure (3 weeks 
before and 4 weeks after vaccination), MAT titers values for C. fetus were less than 2, which are 
considered negative. In week 2 of exposure (week 6 after vaccination), 5 samples were positive 
(titer>4), and in week 9 only 2 heifers were positive. One of 7 positives showed MAT titres of 
32, two were 64, three were 128, and one was 256. Samples, collected in week 16, were all 
negative. Four positive samples were from the treatment group and three were from the control 
group. No significant difference was found by treatment in either the maximum detected titers 
(Tx: median=2, min=2, max=128; C: median=2; min=2, max=256; P=0.57) or the proportion of 
positive titers during the study (Tx=16%; C=12%; OR=1.40, 95% CI: 0.58–3.44; P=0.99).  
ELISA titers for C. fetus results are summarized in the Table 3.5. In a model, including 
treatment, time, and a treatment/time interaction, there was no difference between treatment 
groups in ELISA titres mean before vaccination and exposure (Tx=74, 95% CI: 54–102; C=87, 
95% CI: 61–125; P=0.52). However, there was significant difference between treatment groups 
after vaccination (P<0.02). By week 4 after the second vaccination and immediately before 
exposure, the mean in the treatment group was 3 times higher than of control group (Tx=486, 
95% CI: 412–572; C=169, 95% CI: 119–241; P<0.001). A similar difference was observed in 
week 13 post-vaccination (week 9 of exposure) when titer mean value was the highest during the 
study (Tx=659, 95% CI: 478–909; C=236, 95% CI: 139–401; P<0.001). Titer value mean in 
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treatment group was 2 times higher than in control group in weeks 6 (P=0.02) and week 20 
(P=0.003) post-vaccination (weeks 2 of and 7 after exposure) (Table 3.5).  
Comparing ELISA titers means between the heifers that aborted during the study with those that 
did not, there was no significant difference either in week 2 (aborted=122, 95% CI: 74–200; non-
aborted=283, 95% CI: 129–528; P=0.07), week 9 (aborted =382, 95% CI: 232–628; non-aborted 
=317, 95% CI: 145–696; P=0.70), or week 16 (aborted =153, 95% CI: 93–252; non-aborted =71, 
95% CI: 32–155; P=0.10) after exposure.           
3.5. DISCUSSION 
Herein we compared the pregnancy and infection rates between heifers, vaccinated with a 
polyvalent vaccine, containing C. fetus antigen, to those, vaccinated with a comparable 
polyvalent product that did not contain C. fetus antigen. Heifers were paired by body weight and 
then randomized within each pair into treatment or control group to balance the starting weight 
of the animals and minimize the influence of differences in maturity on cyclicity and immunity. 
Animals in treatment and control groups expressed estrus and were adequately naturally 
challenged. There was no significant difference detected between treatment groups in percentage 
of heifers that became infected with Cfv, proportion of heifers that became pregnant, or 
difference in days to pregnancy. However, serum concentration of C.fetus antibodies, detected by 
ELISA, was significantly higher in treatment group compared to control animals.  
Our visual heat detection and chin-ball markers results suggested that all heifers expressed estrus 
and were mounted by bulls at least once by the day 17 of exposure. This was equally distributed 
between two treatment groups. There was also no difference between treatment groups in the 
time of expressing the first estrus and first bull mounting.  
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We had two naturally infected bulls with the heifers through all 63 days of our study. One of the 
bulls demonstrated significantly higher mounting activity, compare to the other, in the first 12 
days according to the chin-ball marker results. The second bull had been treated for footrot in the 
first week but appeared to respond well to topical therapy. When the more dominant bull was 
replaced due to a toe abscess, there was no difference in breeding activity between two 
remaining bulls from days 13 to 21. However, every bull had similar breeding activity in both 
heifer treatment groups of heifers during the study.          
After exposure to the heifers, the bulls became less likely to culture positive for Cfv, and only 
the one bull, that was with the heifers for the full study, cultured positive consistently during and 
after the study. There was an older study that documented reduced shedding of T. foetus in bulls 
after active breeding and hypothesized that this could happen due to mechanical removal 
microorganisms from penile mucosal membranes during coitus [38]. For the same reason a bull 
cannot be judged free from BGC infection if he fails to infect a single virgin heifer during natural 
service [39]. In case of T. foetus it is not usually found in preputial samples for several days 
subsequent to coitus [38]. Another suggested reason could be contamination with other 
organisms that can overgrow the pathogen of interest during culturing or other DNA can be 
inhibitors for specific primers during PCR. The possible causes of contamination of preputial 
cavity could be masturbation or intermittent prolapsed of mucosal membranes [38]. However, 
these explanations are not conclusive since no publications were found testing such hypothesis. 
Lameness that occurred in two of the bulls remained a concern in terms of overall pregnancy 
outcomes. However, all bulls had satisfactory breeding soundness exams, such as physical 
soundness, scrotal circumference and semen examination [31], and demonstrated good breeding 
activity at the beginning and the end of the trial. The chin-ball marker results and culture-positive 
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rate for Cfv from vaginal mucus in both treatment groups suggested that lameness did not 
impede breeding and adequate challenge.  
One of bulls was cultured positive for Cfv only once during the study which might present a 
concern about adequate challenge of heifers. However, our chin-ball markers results 
demonstrated that all heifers, mounted by that bull, were also mounted by other bulls.  
Overall, 90% of heifers were mounted by more than one bull during the exposure. When heifers, 
mounted by different bulls, were compared in the rate of cultured positive for Cfv at least once 
during the study, it was similarly high (83–91%). Similarly, heifers were cultured a median of 2 
times positive for Cfv during the trial, no matter by which bull they were mounted. Five heifers 
that were mounted only by one bull during the exposure period were cultured positive several 
times during the study, suggesting a satisfactory and uniform challenge.        
In this study, the Cfv infection challenge was achieved as 86% of heifers cultured positive for 
Cfv at least once during the study and there was no significant difference between treatment 
groups but 95% CI of the Odd Ratio was of huge range (0.41–32.7). However, all other 95% CI 
of ORs, combined during this study were within acceptable limits (0.01–5.94), suggesting that an 
issue with “study power” was not a concern; however, it would be prudent to increase the sample 
size in future related studies.  
The difference in “pathogen load” between groups was not assessed since colonies count was not 
performed. This could be considered as one of weaknesses of this study; however, accordingly to 
subsequent conventional PCR results not all submitted colonies were of Cfv. Therefore, 
quantitative analysis of plates was not probably appropriate in this study because some colonies 
might be of Cff and since some plates contained quite big number of colonies it would be 
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difficult to perform Gram-strain and PCR from all of them. The other issue with quantitative 
analysis by colony counts or real-time PCR is that we do not have a consistent sample by weight 
or volume. 
Given that most heifers were cultured positive at least once, and that only 12% were positive 
only once during the study period, it would either appear that transient infections with Cfv were 
uncommon or suggestive of poor culture sensitivity in our study. There were no reports found 
about possibility of BGC transient infection in female cattle.  Moreover, these outcomes indicate 
adequate challenge and exposure of most heifers to more than one infected bull in our study. 
The highest proportion of vaginal mucus samples with Cfv isolated in our study occurred from 
weeks 4 to 6. The results of another similarly organized trial, using commercial and experimental 
polyvalent vaccines, demonstrated the highest proportion of positives in weeks 7–15 [24]. Such 
discrepancy was most likely due to the fact that half of the animals of the earlier trial were also 
challenged at day 39 of breeding season by an intravaginal instillation of Cfv. However, when 
control groups of two studies are compared, the proportion that cultured positive in weeks 4–6 
was similar in both studies (around 25–40%).  
Uterine secretions in cattle are characterized by greater concentrations of IgG than IgA 
[reviewed in 35]. In some animal models, vaginal or nasal application of antigens resulted in 
optimal uterine responses, but this has not been established for cattle [reviewed by 40]. If the 
latter were demonstrated in cattle, the goal of Cfv vaccination would be stimulation of systemic 
IgG production for subsequent secretion within the uterine mucus.  
The efficacy of commercially available polyvalent vaccines against BGC could also depend on 
the adjuvants used. The majority of vaccines against C. fetus are prepared with oil or aluminum 
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hydroxide adjuvants [11, 13, 14, 21, 41]. Aluminum hydroxide is able to induce a good antibody 
(Th2) response; however, it has little capacity to stimulate cellular (Th1) immune responses [42] 
due to its poor adjuvant effect on polysaccharide antigens, and can increase IgE production [43]. 
The most effective vaccines are prepared with oil adjuvants [reviewed in 13]. They stimulate 
strong antibody and cell-mediated responses but may cause a granuloma at the injection site [13, 
24, 42]; however, newer oil containing adjuvants are much improved [13, 42].  
In our study, pregnancy rates were low for both treatment groups (Tx=48% and C=36%). Beef 
heifers commonly have pregnancy rates >95% after 63 days of bull exposure [44]. However, the 
percentage of non-pregnant heifers was consistent with a reported natural outbreak of BGC in 
western Canada [45].  
The overall proportion of pregnant heifers was not significantly different between the two 
vaccination groups and was in agreement with another vaccine trial with two commercial 
vaccines [22]. In that study 16 heifers were vaccinated parentally twice, 6 and 3 weeks before 
breeding, with a polyvalent vaccine containing Cff and Cfv and subsequently served by an 
infected bull for 60 days. The result was limited because of the low number of animals, but the 
two commercial vaccines were not efficient in improving pregnancy rate. Another reason of poor 
results from that study was apparently poor immune response to vaccination. The increase of 
antibodies to C. fetus was not detected post vaccination either in vaginal mucus samples by IFAT 
or in serum by ELISA [22]. Therefore, it is difficult to say whether small sample size was the 
main reason for the negative results of vaccination in that trial.   
Another study compared polyvalent vaccines that contained Tritrichomonas foetus, Cfv, as well 
as other common pathogens, given subcutaneously, and an experimental vaccine, applied 
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subcutaneously and intravaginally, that contained only T. foetus and C. fetus subspecies, 
originally isolated from a cow with pyometra, together with an oleo adjuvant. All heifers were 
exposed to naturally infected bulls over a 90-day period. The results indicated that the 
experimental vaccine yielded superior protection (significantly higher pregnancy rates) 
compared to the commercial vaccine [24].  
When considering the pregnancy rates in our study, it is important to recognize that the heifers 
remained exposed to the bulls long enough to get pregnant, abort and become pregnant again. A 
total of 50% of the heifers that were pregnant at the end of the study, had aborted earlier. Only 6 
heifers never aborted during the study and maintained pregnancy up to the end.  
Pregnancy rates in both treatment groups were very poor by industry standards. All bulls used in 
our study had undergone a breeding soundness examination before the trial began and 
demonstrated satisfactory results. There is no published evuidence to suggest that BCG 
negatively effects spermatozoa. Actually, there is a study demonstrated that T. foetus is able to 
adhere to sperm cells resulting in agglutination, immune reaction and reducing motility of 
sperms [46, 47]. In addition, T. foetus expresses a cystein protease that responsible for cytotoxic 
effect against sperms [47]. However, there is no data found determined the effect of Cfv. The 
Cfv has not been isolated from accessory glands or epididimis and its presence in bull ejaculate 
is believed to be due to contamination of preputial cavity [48, 49]. Therefore, Cfv would rather 
not influence sement quality.      
In this study, the time to first detected pregnancy in all heifers, detected pregnant during the 
study, those that remained pregnant at the end of the study, and pregnant heifers that never 
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aborted during the study, did not differ by treatment. Therefore, vaccination against BGC with 
polyvalent product did not significantly shorten time to conception  in our study.   
Ultrasound and serum PSPB gave similar pregnancy results and similar kappa values in our 
study, compare to published data [50]. Most of the disagreements were in the first weeks of the 
experiment. Early pregnancies could cause an increased concentration of PSPB, but could be 
missed by ultrasound. PSPB has been reported to detect as early as 16 days of pregnancy [51], 
which is earlier than the 26–28 days of detection for ultrasound [52]. In this study we utilized the 
kit that should detect pregnancy from 28 days after breeding with 99% of acuracy [34]. 
However, we estimated the detected pregnancies in our study by PSPB from 12 days. PSPB level 
also remained elevated for a period after pregnancy loss, which could potentially result in 
misclassification, but we also used ultrasound and compared the results. In this study, PSPB 
blood level was only elevated once in two animals at the beginning of the trial, that never 
consequently confirmed by ultrasound. Therefore, in most cases we were able to estimate 
pregnancy term when detected by the serum level of PSPB.   
More than half of the heifers in this study never detected pregnant by ultrasound or serum PSPB. 
The question remains, were they never pregnant or did they have early embryonic loss? It is 
often cited that Cfv results in pregnancy loss at 60–75 days post-breeding [1, 10], but based on 
earlier methods of detection (ultrasound and PSPB) losses could occur earlier. In our study the 
earliest pregnancies, detected by ultrasound, were about 25 days that were confirmed by serum 
level of PSPB. Sometimes pregnancies were detected by PSPB and were not confirmed by 
ultrasound and if not detected at the next week we estimated that abortion happened before 25 
days of pregnancy. We estimated that most abortions happened before day 35 of gestation. 
Abortion rates did not differ by vaccination group. 
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We could not determine whether immunity improved after abortion (reconvalescent immunity), 
based on MAT, since a low number of titer-positives was detected throughout the study. 
However, the ELISA results allow  the conclusion that there was no significant difference in 
serum concentrations of IgG to C. fetus  between heifers that aborted during the study and those 
that did not.  
Very few MAT-positive titers were detected during our study, resulting in no significant 
differences by week or treatment. After systemic immunization, antibodies of IgG and IgM 
classes were commonly detectable in serum, while IgA and IgG1 were transported across the 
epithelium into genital secretions [53]. ELISA is suggested as the best monitoring test for 
systemic antibodies against Campylobacter spp [54]. In our study, significant rise of systemic 
IgG antibodies to C. fetus titers in treatment group was detected by ELISA that was significantly 
higher than in control group. In contrast, ELISA did not detect any significant rise in systemic 
IgG antibody titers after systemic immunization in another vaccine trial where aluminum 
hydroxide adjuvant was used; there was only slight increase in antibody concentrations 
immediately after the breeding period. This may have been due to natural exposure to Cfv 
antigens in the semen of the infected bull [22].   
In our study significant rises in antibody titers were detected by ELISA in treatment group by 
week 4 after vaccination, right before heifers were exposed to bulls. During the bull exposure 
period antibody titers in the treatment group were significantly higher than that of the control 
group.  This suggests that ELISA could be a more sensitive method to monitor the systemic 
antibody response to Cfv after vaccination than the MAT technique since MAT measures only 
surface antigens but ELISA is able to detect internal and external antigens of bacterial cells [54]. 
It has been suggested that antigenic differences between strains may cause the lack of 
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effectiveness of the vaccines [24]. However, the commercial vaccine was able to induce antibody 
responses, detected by ELISA, that were significantly higher after vaccination in the treatment 
group of heifers, compared to thecontrol group. Alternatively, even though the antibody 
responses in treatment groups were statistically higher, they may have been higher if the animals 
had been immunized with antigens more similar to the infecting strain.     
It was suggested that aluminum hydroxide generally induces an immunity of shorter duration 
than an oil adjuvant vaccine [55]. Using oleo adjuvant induced significant antibody response that 
was detected by C. fetus-IgG ELISA test [24]. In our study, the serum level of antibodies to C. 
fetus was continuously more than 2 times higher in treatment group of heifers, compared to 
control animals, for about 5 months post vaccination (time of the last sampling). Unfortunately, 
we could not determine whether the antibody level was increased in the subsequent months. 
Sampling was stopped at week 12 of bull exposure  as interpreting the results became more 
difficult due to the confounding of natural infection as heifers aborted and became pregnant 
again.  
3.6. CONCLUSIONS  
Vaccination of heifers with a polyvalent commercial vaccine, containing C. fetus antigen, 
according to the label did not significantly reduce infection rates or improve pregnancy rate 
when compared to heifers vaccinated with a similar polyvalent commercial vaccine that did not 
contain C. fetus antigen, when exposed to Cfv-infected bulls.  
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Table 3.1. Peer-reviewed studies regarding vaccination for Bovine Genital 
Campylobacteriosis   
Study Vaccine 
type 
Animals, sex 
and number  
Vaccine 
route  
Challenge Authors’ 
conclusion 
Clark et al, 1968 [15] Monovalent, 
experimental  
Bulls, n=4 Systemic  Culture infusion Effective 
Allan and Mutch, 1971 
[26] 
Monovalent, 
commercial 
Heifers, n=334 Systemic Natural exposure Effective 
Allan, 1972 [18] Monovalent, 
commercial 
Heifers, n=261  Systemic 
 
Natural exposure 
 
Effective 
Bulls, n=70 Questionable 
Clark et al, 1972 [27] Monovalent, 
experimental 
Heifers, n=125 Systemic 
 
Natural exposure  
Culture infusion 
Effective 
Clark et al, 1972 [28] Monovalent, 
experimental 
Heifers, n=80 Systemic 
 
Natural exposure  
Culture infusion 
Effective 
Clark et al, 1972 [20] Monovalent, 
experimental 
Cows, n=102 Systemic Natural exposure Effective 
Bouters et al, 1973 [14] Monovalent, 
experimental 
Bulls, n=321 Systemic Natural exposure Effective  
Shurig et al, 1975 [25] Monovalent,  
experimental 
Heifers, n=16 Systemic Culture infusion Effective 
Clark et al, 1976 [19] Monovalent,  
experimental 
Heifers, n=80 
Bulls=13 
Systemic Culture infusion Effective 
Johns et al, 1977 [21] Monovalent, 
commercial  
Heifers, n=33 Systemic Culture infusion Effective 
Shurig et al, 1978 [23] Monovalent, 
experimental 
Heifers, n=32 Systemic Culture infusion Effective 
Clark et al, 1982 [11] Monovalent, 
commercial  
Bulls, n=24 Systemic Culture infusion Effective 
Vasquez et al, 1983 [17] Monovalent, 
commercial  
Bulls, n=12 Systemic Culture infusion 
Natural exposure 
Effective 
Eaglesome et al, 1986 [16] Monovalent,  
experimental 
Heifers, n=46 
Bulls, n=4 
Systemic Natural exposure Effective 
Cobo et al, 2003 [22] Polyvalent, 
commercial 
Heifers, n=24 Systemic Natural exposure Questionable 
Cobo et al, 2004 [24] Polyvalent, 
commercial 
Heifers, n=31 Systemic Natural exposure  
Culture infusion 
Both effective, 
Experimental– 
superior effect   Monovalent,  
experimental 
Heifers, n=31 Systemic
Local 
Natural exposure 
Culture infusion 
Foscolo et al, 2005 [15] Monovalent,  
experimental 
Bulls, n=27 Systemic Naturally infected 
before trial 
Questionable 
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Table 3.2. Timeline for sample and data collection. Including dates of vaccination, bull 
exposure, preputial sampling, vaginal mucus collection, blood collection, 
transrectal ultrasonography and visual heat detection 
  
Date 
  
Day 
  
Wk 
Vaccination 
 B
u
ll
 E
x
p
o
su
re
 
Sample and Data Collection 
P
re
p
u
ti
al
 S
am
p
le
 
V
ag
in
al
 M
u
cu
s 
Blood 
T
ra
n
s 
-R
ec
ta
l 
U
lt
ra
so
u
n
d
 
V
is
u
al
 H
ea
t 
D
et
ec
ti
o
n
 
V
is
ta
 5
 V
L
5
 
V
is
ta
 5
 
L
5
 
C
. 
fe
tu
s 
ti
te
r 
P
re
g
n
an
cy
 
S
p
ec
if
ic
 
P
ro
te
in
 B
 
20-May-13 -49 -7 Yes Yes 
 
Yes 
 
Yes 
   
10-Jun-13 -28 -4 Yes Yes 
 
Yes Yes 
  
Yes 
 
08-Jul-13 0 0 
  
Yes Yes 
 
Yes 
 
Yes Yes 
15-Jul-13 7 1 
  
Yes Yes Yes 
   
Yes 
22-Jul-13 14 2 
  
Yes Yes Yes Yes Yes 
 
Yes 
29-Jul-13 21 3 
  
Yes Yes Yes 
 
Yes 
 
Yes 
05-Aug-13 28 4 
  
Yes Yes Yes 
 
Yes Yes 
 
12-Aug-13 35 5 
  
Yes Yes Yes 
 
Yes Yes 
 
19-Aug-13 42 6 
  
Yes Yes Yes 
 
Yes Yes 
 
26-Aug-13 49 7 
  
Yes Yes Yes 
 
Yes Yes 
 
02-Sep-13 56 8 
  
Yes Yes Yes Yes Yes Yes 
 
09-Sep-13 63 9 
  
Yes Yes Yes 
 
Yes Yes 
 
16-Sep-13 70 10 
    
Yes 
 
Yes Yes 
 
23-Sep-13 77 11 
       
Yes 
 
30-Sep-13 84 12 
    
Yes 
  
Yes 
 
07-Oct-13 91 13 
       
Yes 
 
14-Oct-13 98 14 
    
Yes 
  
Yes 
 
21-Oct-13 105 15 
       
Yes 
 
28-Oct-13 112 16 
    
Yes Yes 
 
Yes 
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Table 3.3. The optical density (OD) values of PSPB concentration for determining 
Pregnant/Non-Pregnant status in BioPRYN assay  
Not Pregnant Low Recheck Cutoff High Recheck Pregnant 
OD < 0.135 OD = 0.135 to 0.15 0.15 OD = 0.15 to 0.21 OD > 0.21 
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Table 3.4. Summary of the bull preputial culture, confirmed by multiplex conventional 
PCR, and real-time PCR results for Campylobacter fetus subsp. venerealis 
before, during and after the periods of exposure to heifers  
Week Bulls 
953 19U TD 
Results Exposure Results Exposure Results Exposure 
C
u
lt
u
re
 
R
ea
l-
ti
m
e 
P
C
R
 
C
u
lt
u
re
 
R
ea
l-
ti
m
e 
P
C
R
 
C
u
lt
u
re
 
R
ea
l-
ti
m
e 
P
C
R
 
-9 
B
ef
o
re
  
b
re
ed
in
g
  + + n/a* + + n/a + + n/a 
-8 + + n/a + + n/a – + n/a 
-7 + + n/a + + n/a + + n/a 
-6 + + n/a + + n/a + + n/a 
0 
D
u
ri
n
g
 b
re
ed
in
g
 p
er
io
d
 + n/a + + n/a + + n/a – 
1 – n/a + – n/a + – n/a – 
2 – – – – + + – + + 
3 n/a n/a – – – + – – + 
4 n/a n/a – – + + + + + 
5 n/a n/a – + + + – – + 
6 n/a n/a – + + + – – + 
7 n/a n/a – + + + – – + 
8 n/a n/a – – – + – – + 
9 n/a n/a – – – + – – + 
+2 
A
ft
er
 
b
re
ed
in
g
 + + n/a + – n/a – – n/a 
+4 – – n/a – – n/a + – n/a 
+17 – – n/a + + n/a – – n/a 
+21 – – n/a + + n/a – – n/a 
 *n/a- not aplicable  
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Figure 3.1. Percentage of vaginal mucus samples, cultured positive for Cfv and confirmed 
by multiplex conventional PCR, by week and treatment (errors bars represents 
standard errors (SE))  
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Figure 3.2a and 3.2b. Proportion of detected pregnant in both groups during the trial by 
week and treatment (errors bars represents SE) 
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Figure 3.3. ELISA antibody to C. fetus titers results by week of study and treatment groups 
(errors bars represents 95% CI) 
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Supplemental Table 3.1. Comparison of samples, cultured positive for Cfv and confirmed 
by multiplex conventional PCR, by treatment groups  
Weeks 
of 
study 
Cultured positive, % OR 95% CI P-value* 
Tx (n=25) C (n=25) 
Proportion 95% CI Proportion 95% CI 
2 4 0–12 8 0–19 0.48 0.04–5.65 0.56 
3 24 7–41 32 14–50 0.67 0.19–2.33 0.53 
4 36 17–55 24 7–41 1.78 0.52–6.09 0.36 
5 28 10–46 24 7–41 1.23 0.35–4.37 0.75 
6 36 17–55 40 21–59 0.84 0.27–2.65 0.77 
7 28 10–46 28 10–46 1.00 0.29–3.44 0.99 
8 4 0–12 28 10–46 0.11 0.01–0.95 0.04 
9 16 2–30 32 14–50 0.40 0.10–1.57 0.19 
10 16 2–30 20 4–36 0.76 0.18–3.25 0.71 
12 24 7–41 40 21–59 0.47 0.14–1.60 0.23 
14 12 1–25 28 10–46 0.35 0.08–1.55 0.17 
16 12 1–25 28 10–46 0.35 0.08–1.55 0.17 
  *Represents difference between treatment and control groups by week in a model 
accounting for repeated measures and including treatment, time, and treatment*time interaction. 
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Supplemental Table 3.2a. Comparison of detected pregnant (by PSPB) by treatment 
groups  
Weeks 
of 
study 
Detected pregnant by PSBP, % OR 95% CI P-value* 
Tx (n=25) C (n=25) 
Proportion 95% CI Proportion 95% CI 
4 8 0–19 0 0 n/a n/a n/a 
5 16 2–30 8 0–19 2.19 0.36–13.21 0.39 
6 16 2–30 16 2–30 1.00 0.22–4.53 0.99 
7 16 2–30 12 1–25 1.40 0.27–7.00 0.68 
8 12 1–25 12 1–25 1.00 0.18–5.51 0.99 
9 12 1–25 16 2–30 0.72 0.14–3.59 0.68 
10 20 4–36 12 1–25 1.83 0.39–8.67 0.44 
11 28 10–46 16 2–30 2.04 0.51–8.12 0.31 
  *Represents difference between treatment and control groups by week in a model 
accounting for repeated measures and including treatment, time, and treatment/time interaction. 
 
 
Supplemental Table 3.2b. Comparison of detected pregnant (by ultrasound) by treatment 
groups 
Weeks 
of 
study 
Detected pregnant by ultrasound, % OR 95% CI P-value* 
Tx (n=25) C (n=25) 
Proportion 95% CI Proportion 95% CI 
5 12 1–25 8 0–19 1.57 0.24–10.30 0.64 
6 20 4–36 12 1–25 1.83 0.39–8.67 0.44 
7 16 2–30 16 2–30 1.00 0.22–4.54 0.99 
8 8 0–19 12 1–25 0.64 0.10–4.19 0.64 
9 12 1–25 12 1–25 1.00 0.18–5.51 0.99 
10 20 4–36 12 1–25 1.83 0.39–8.67 0.44 
11 16 2–30 20 4–36 0.76 0.18–3.25 0.71 
12 28 10–46 24 7–41 1.23 0.35–4.37 0.75 
13 28 10–46 28 10–46 1.00 0.29–3.44 0.99 
14 28 10–46 24 7–41 1.23 0.35–4.37 0.75 
15 28 10–46 20 4–36 1.55 0.42–5.78 0.51 
16 28 10–46 16 2–30 2.04 0.51–8.12 0.31 
  *Represents difference between treatment and control groups by week in a model 
accounting for repeated measures and including treatment, time, and treatment/time interaction. 
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Supplemental Table 3.3. Comparison of ELISA antibody to C. fetus titers results by 
treatment groups 
Week after 
vaccination 
Week of 
exposure  
Treatment groups, n=25 per group P-value* 
Tx (Vaccine with C. 
fetus antigen) 
C (Vaccine without C. 
fetus antigen) 
Mean 95% CI Mean 95% CI 
0 -7 74 54 102 87 61 125 P=0.55 
4 0 486 412 572 169 119 241 P<0.001 
6 2 184 129 262 99 65 149 P=0.02 
13 9 659 478 909 236 139 401 P<0.001 
20 +7 211 144 310 96 65 141 P=0.003 
 *Represents difference between treatment and control groups by week in a model 
accounting for repeated measures and including treatment, time, and treatment/time interaction. 
 
  
126 
 
3.7. REFERENCES: 
1. Bondurant RH. 2005. Venereal diseases of cattle: natural history, diagnosis, and the role of 
vaccines in their control. Vet Clin North Am Food Anim Pract; 21(2): 383–408. 
2. Campero CM, Moore DP, Oden AC, Cipolla AL, Odriozola E. 2003. Aetiology of bovine 
abortion in Argentina. Vet Res Commun; 27(5): 359–369. 
3. Givens MD. 2006. A clinical evidence-based approach to infectious causes of infertility in 
beef cattle. Theriogenology; 66(3): 648–654. 
4. McCool CJ, Townsend MP, Wolfe SG, Simpson MA, Olm TC, Jayawardhana GA. 1988. 
Prevalence of bovine venereal diseases in the Victoria River district of the northern territory: 
likely economic effects and practicable control measures. Aust Vet J; 65(5): 153–156. 
5. Finlay RC, Ruckerbauer GM, Stovell PL. 1985. Campylobacter fetus in artificial insemination 
unit and slaughterhouse bulls in Ontario. Can J Comparative Med; 49(2): 231–232. 
6. Bawa EK, Adekeye JO, Oyedipe EO, Omoh JU. 1991. Prevalence of bovine 
campylobacteriosis in indigenous cattle of three states in Nigeria. Trop Anim Health Prod; 
23(3): 157–160. 
7. Hum S. 1987. Bovine abortion due to Campylobacter fetus. Aust Vet J; 64(10): 319–320. 
8. van Bergen MA, Linnane S, van Putten JP, Wagenaar JA. 2005. Global detection and 
identification of Campylobacter fetus subsp. venerealis. Rev Sci Tech; 24(3): 1017–1026. 
9. Hoffer MA. 1981. Bovine campylobacteriosis: a review. Can Vet J; 22(11): 327–330.  
10. Bondurant RH. 1999. Inflammation in the bovine female reproductive tract. J Anim Sci; 
77(Suppl 2): 101–110. 
11. Clark BL, Dufty JH. 1982. The duration of protection against infection with Campylobacter 
fetus subsp. venerealis in immunised bulls. Aust Vet J; 58(5): 220. 
127 
 
12. Sanderson MW, Dargatz DA, Garry FB. 2000. Biosecurity practices of beef cow-calf 
producers. JAVMA; 217(2): 185–189.  
13. Clark BL, Dufty JH, Monsbourgh MJ. 1968. Vaccination of bulls against bovine vibriosis. 
Aust Vet J; 44: 530. 
14. Bouters R, De Keyser J, Vandeplassche M, Van Aert A, Brone E, Bonte P. 1973. Vibrio fetus 
infection in bulls: curative and preventive vaccination. Br Vet J; 129: 52–57. 
15. Foscolo CB, Pelegrin AO, Leite RC, Stynen APR, Lage AP. 2005. Vaccination of bulls 
against bovine genital campylobacteriosis: a therapeutic approach. Anim Reprod; 2(2): 122–
127. 
16. Eaglesome MD, Garcia MM, Hawkins CF, Alexander FC. 1986. Vaccination studies for the 
control of campylobacteriosis in Jamaican cattle. Vet Rec; 119(2): 299–301 (Abstract). 
17. Vasquez LA, Ball L, Bennett BW, Rupp GP, Ellis R, Olson JD, Huffman MH. 1983. Bovine 
genital campylobacteriosis (vibriosis): vaccination of experimentally infected bulls. Am J 
Vet Res; 44(8): 1553–1556.  
18. Allan PJ. 1972. A field evaluation of vaccination of bulls against bovine vibriosis. Aust Vet J; 
48: 72–73. 
19. Clark BL, Dufty JH, Monsbourgh MJ, Parsonson IM. 1976. Immunization against bovine 
vibriosis due to Campylobacter fetus subsp. fetus biotype intermedius. Aust Vet J; 52: 362–
364. 
20. Clark BL, Fitzpatrick DH. 1972. Vaccination against bovine vibriosis in a commercial beef 
herd in Victoria. Aust Vet J; 48: 385–387.  
21. Johns DR, Mater RJ, Medveczky NE. 1977. Bovine vibriosis vaccination. Aust Vet J; 53(10): 
467–469.  
128 
 
22. Cobo ER, Cipolla A, Morsella C, Cano D, Campero C. 2003. Effect of two commercial 
vaccines to Campylobacter fetus subspecies on heifers naturally challenged. J Vet Med B 
Infect Dis Vet Public Health; 50: 75–80.   
23. Schurig GG, Duncan JR, Winter AJ. 1978. Elimination of Genital Vibriosis in female cattle 
by systemic immunization with killed cels or cell-free extracts of Campylobacter fetus. J of 
Inf Dis; 138(4): 463–472.  
24. Cobo ER, Morsella C, Cano D, Cipolla A, Campero C. 2004. Immunization in heifers with 
dual vaccines containing Tritrichomonas foetus and Campylobacter fetus antigens using 
systemic and mucosal routes. Theriogenology; 62: 1367–1382.   
25. Schurig GG, Hall CE, Corbell LB, Duncan JR, Winter AJ. 1975. Bovine veneral vibriosis: 
cure of genital infection in females by systemic immunization. Inf Immunol; 11: 245–251. 
26. Allan PJ, Mutch CB. 1971. The effect of vaccination against bovine vibriosis on pregnancy 
rates in heifers in a Northern Queensland beef herd. Aust Vet J; 47: 184–185. 
27. Clark BL, Dufty JH, Monsbourgh MJ. 1972. Comparison of the protective properties of 
bacterins prepared by two methods. Aust Vet J; 48: 376–381. 
28. Clark BL, Dufty JH, Monsbourgh MJ. 1972. Studies on immunization against bovine 
vibriosis of yearlings and calves. Aust Vet J; 48: 382–384. 
29. Petrie A, Watson P. 2013. Statistics for veterinary and animal science. 3-rd Edition. Oxford: 
Wiley-Blackwell. 
30. Chaban B, Chu S, Hendrick S, Waldner C, Hill JE. 2012. Evaluation of a Campylobacter 
fetus subspecies venerealis real-time quantitative polymerase chain reaction for direct 
analysis of bovine preputial samples. Can J of Vet Res; 76: 166–173.  
129 
 
31. Barth AD. 2013. Bull breeding soundness evaluation manual, 3
nd
 Edition. Saskatoon: The 
Western Canadian Association of Bovine Practitioners. 
32. Chaban B, Garcia Guerra A, Hendrick SH, Waldner CL, Hill JE. 2013. Isolation rates of 
Campylobacter fetus subsp venerealis from bovine preputial samples via passive filtration 
on nonselective medium versus selective medium, with and without transport medium. Am J 
Vet Res.; 74(8): 1066–1069. 
33. Hum S, Quinn K, Brunner J, On SL. 1997. Evaluation of a PCR assay for identification and 
differentiation of Campylobacter fetus subspecies. Aust Vet J; 75: 827–831. 
34. Gabor G, Toth F, Ozsvari L, Abonyi-Toth Zs, Sasser RG. 2007. Early detection of pregnancy 
and embryonic loss in dairy cattle by ELISA tests. Reprod in Dom Anim; 42(6): 633–636.  
35. Repiso MV, Baraibar MA, Olivera MA, Silveyra S, Battistoni J. 2002. Development and 
evaluation of an enzyme-linked immunosorbent assay for quantification of the humoral 
response of cattle vaccinated against Campylobacter fetus. AJVR; 63(4): 586–590. 
36. Dohoo I, Martin W, Stryhn H. 2003. Veterinary epidemiologic research. Charlottetown, PEI, 
Canada: AVC Inc; 502–504.  
37. Ballinger GA. 2004. Using Generalized Estimating Equations for longitudinal data analysis. 
Organizational Res Methods; 2: 127–150. 
38. Barlett DA, Hasson EV, Teeter KG. 1947. Occurrence of Trichomonas foetus in preputial 
samples from infected bulls. J Am Vet Med Assoc; 110(839): 114–120. 
39. Newsam IDB. 1960. Experimental Vibrio fetus infection in heifers. Part 1. Infection and 
conception rates and diagnosis. The Aust Vet J; 11: 426–431. 
40. Gilbert R.O. 2013. Immune response of the reproductive tract to infectious agents. Rev Bras 
Reprod Anim, Belo Horizonte; 37(2): 196–197.   
130 
 
41. Clark BL, Dufty JH. 1982. The duration of protection against infection with Campylobacter 
fetus subsp. venerealis in the immunized bulls. Aust Vet J, 58: 220. 
42. Petrovsky N, Aguilar JC. 2004. Vaccine adjuvants: Current state and future trends. 
Immunology and Cell Biology; 82: 488–496. 
43. Lindblad E. 2004. Aluminium adjuvants – in retrospect and prospect. Vaccine; 22: 3658–
3668. 
44. Dziuk PJ, Bellows RA. 1983. Management of reproduction of cattle, sheep, and pigs. J Anim 
Sci; 57(Suppl. 2): 355–379. 
45. Waldner C, Hendrick S, Chaban B. 2013. Application of a new diagnostic approach to a 
bovine genital campylobacteriosis outbreak in a Saskatchewan beef herd. Can Vet J; 54(4): 
373–376.  
46. Benchimol M, Rosa ID, Fontes RD, Dias AJB. 2008. Trichomonas adhere and phagocytose 
sperm cells: adhesion seems to be a prominent stage during interaction. Parasitol Res; 102: 
597–604. 
47. Ribeiro CM, Falleiros MB, Bicudo SD, Araujo Jn JP, Golim MA, Silva Filho FC, Padovani 
CR, Modolo JR. 2010. Tritrichomonas foetus extracellular products decrease progressive 
motility of bull sperm. Theriogenology; 73: 64–70. 
48. Parsonson IM, Clark BL, Dufty L. 1974. The pathogenesis of Tritrichomonas foetus infection 
in the bull. Aust Vet J; 50: 421–423.  
49. Rhyan JC, Wilson KL, Wagner B, Anderson ML, Bondurant RH, Burgess DE, Mutwiri GK, 
Corbeil LB. 1999. Demonstration of Tritrichomonas foetus in the external genitalia and of 
specific antibodies in preputial secretions of naturally infected bulls. Vet Pathol; 36: 406–
411. 
131 
 
50. Romano E, Larson J. 2010. Accuracy of pregnancy specific protein-B test for early 
pregnancy diagnosis in dairy cattle. Theriogenology; 74(6): 232–239.   
51. Sasser RG, Ruder CA, Ivani KA, Butler JE, Hamilton WC. 1986. Detection of pregnancy by 
radioimmunoassay of a novel pregnancy-specific protein in serum of cows and a profile of 
serum concentrations during gestation. Bio Reprod; 35: 936–942. 
52. Romano JE, Thompson JA, Forrest DW, Westhusin ME, Tomaszweski MA, Kraemer DC. 
2006. Early pregnancy diagnosis by transrectal ultrasonography in dairy cattle. 
Theriogenology; 66(4): 1034–1041.  
53. Corbeil LB, Campero CM, Rhyan JC, BonDurant RH.  2003. Vaccines against sexually 
transmitted diseases. Reprod Biol and Endocrinol; 1: 118–124.  
54. Turan N, Ak S, Ak K, IlerikK, Ilgaz A. 2000. Use of ELISA, IFA, and avidin-biotin staining 
for the diagnosis of bovine genital campylobacteriosis. Turk J Vet Anim Sci; 24: 113–121. 
 55. Corbeil L, Bondurant R. 2001. Immunity to bovine reproductive infections. Vet Clin North 
Am: Food Ani. Prac; 17: 567–583.  
 
  
132 
 
4. GENERAL DISCUSSION AND FUTURE RESEARCH 
4.1. GENERAL DISCUSSION 
This thesis describes the comparison of diagnostic approaches to detect Campylobacter fetus 
subsp. venerealis (Cfv) and evaluates the efficacy of vaccination for Bovine Genital 
Campylobacteriosis (BGC). Different bovine vaginal mucus sample preparation methods for 
real-time PCR were compared in order to detect Cfv and the efficacy of a polyvalent commercial 
vaccine in preventing infection and reproductive loss in cattle was evaluated.  
C. fetus is divided into two subspecies, Cff and Cfv, which are different in their epidemiologic 
and clinical importance; therefore, differentiation on the subspecies level is important. 
Conventional PCR, based on two primer pairs (one targets the carbon starvation gene in both 
subspecies, while another targets the parA gene in Cfv), had high agreement with other typing 
methods when done directly from colonies [1, 2]. A real-time PCR, targeting the parA gene in 
Cfv, was successfully utilized for bull preputial samples [3] but required adaptation of the 
sample preparation method on bovine vaginal mucus.  
Innate immunity is a vital protection mechanism for exposed female cattle [4]. Acquired immune 
response is also important. Mucus membranes of the uterus are characterized by a greater IgG 
than IgA response [5]. Vaccine-induced immunity is usually effective but short-lived and annual 
booster is required [6]. The efficacy of vaccines depends on the antigens and adjuvants they 
contain [7]. There are relatively limited number of peer-reviewed studies about vaccination for 
BGC, most of which more than 30 years old and focused on monovalent experimental 
vaccination. Only couple more recent studies where found describing the effectiveness of 
commercial polyvalent vaccines. Since polyvalent commercial vaccines are more convenient to 
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use for beef producers than monovalent experimental vaccines, there is a need to better 
understand the efficacy of vaccination with a commercially available polyvalent vaccine.   
The purpose of this chapter is to summarize the main findings obtained from the two studies in 
this thesis. The strengths and limitations, experienced during these studies will be discussed and 
potential improvement for future studies will be explored. Finally, necessary conclusions will be 
made.  
In the first study’s (Chapter 2) the results of Cfv real-time PCR were compared for bovine 
vaginal mucus samples, prepared using heat lysis and magnetic bead based sample preparation 
techniques, to results of direct, selective culture of the CVM. The sample processing method, 
designed and successfully applied for bull preputial samples [3], did not demonstrate adequate 
sensitivity when applied on vaginal mucus. All modifications of that heat lysis protocol 
demonstrated low sensitivity when were compared to culture confirmed by conventional PCR.  
The magnetic bead-based extraction method tended to be the comparatively more sensitive than 
heat lysis methods but required much of time and resources to perform. 
One possible explanation for low sensitivity of the sample processing method, designed and 
successfully applied for bull preputial samples [3], could be different biophysical properties of 
vaginal mucus, compare to preputial scrape material. Nucleic acid isolation protocol, designed 
for preputial samples, contained several steps to eliminate possible inhibitors [3]. Even though, 
quantification analysis was not done, the modifications of heat lysis sample processing protocol, 
initially designed for prepuce samples, employing fewer dilution steps had greater sensitivity in 
this study.  
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The aqueous phase of bovine CVM contains low-molecular-mass compounds [8] and the gel 
phase is formed mainly by insoluble high-molecular-mass compounds [9]. The gel phase is 
probably responsible for high viscosity of CVM in certain stages of estrus cycle [10]. Properties 
of CVM depend on the stage of estrus cycle [9]: CVM becomes less viscous and more hydrated 
during the pre-ovulatory period [10] and vice versa in the luteal phase [10–12]. An inverse 
relationship between the dry matter content in CVM and the degree of crystallization was noted 
[11]. Reduction in the proportion of salts in aqueous phase leads to reduction of water content, 
consequent reduction in crystallization and relative increase of other salt components in the dry 
residue. At the estrus dry matter concentration is minimum and crystallization is maximum [12, 
13]. Therefore, CVM often has gelly appearance due to either high viscosity or crystallization, 
and this does not depend on the stage of estrus cycle, during which sampling was performed.    
Different DNA isolation protocols can be utilized on clinical samples. In one study, the 
VenSF/VenSR-based PCR on the samples, collected mainly during the estrous cycle, incubated 
in TEM at 37°C for 5 days and processed with CTAB, provided Cfv detection in 24% cases, 
compared to 2.8% by bacterial isolation in culture [13]. This large number of detected positives 
was most likely due to maintaining viability of the pathogen in that study. In our study, however, 
some modifications were made to the existing heat lysis isolation protocol, skipping some steps, 
in order to test a rapid sample preparation method that could be used on field samples. When 
modified protocols were compared to culture, the most adequate results were obtained by 
performing protocols with fewer dilution steps. The two most sensitive heat lysis isolation 
methods were consequently compared to a magnetic bead-based extraction method that 
described as demonstrated satisfactory results in different samples for a variety of pathogens 
[14–16].   
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All compared isolation methods had low sensitivity in relation to culture, confirmed by multiplex 
conventional PCR. That could be explained by several reasons. The first explanation is the 
possibility that culture, confirmed by conventional PCR actually was not the gold standard. 
However, we detected more positives by culture, confirming by conventional PCR, than by real-
time PCR. On other hand, samples were kept under ideal conditions prior to culturing, which is 
not always practical. Another explanation for the low sensitivity of the tested methods is that the 
freeze-thaw process, which can disrupt cellular compartments [17], was repeated several times in 
our study. Therefore, further testing of the DNA isolation methods should be performed utilizing 
cryoprotectants or on fresh samples.  
Theoretically, there might be a chance that results of our study were confounded by the fact that 
the primers for the PCR assay were not specific enough for Cfv. However, it is difficult to make 
any conclusion in this time since none of measurements were performed regarding this matter. It 
had been believed that the parA gene is the unique to Cfv [18, 19]; however, motility genes were 
recently identified, suggesting the possibility of the gene’s horizontal transport [19, 20], but this 
needs to be further investigated. In other hand, if the parA gene was transferred to other 
Campylobacter strains we would probably have more positives detected by real-time PCR than 
by culture. In addition, this potential source of error was equally distributed between all 
compared protocols.  
 Even though the magnetic bead-based protocol was the most sensitive in our study, it required 
more time and resources to perform than heat lysis protocols, and the specificity of all these 
methods was similarly high. The easiest to perform heat lysis protocol did not significantly differ 
from the magnetic bead-based isolation method in either sensitivity or specificity and can be 
potentially utilized for vaginal mucus.   
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In the chapter 2 the biggest number of positive samples was detected with selective culture of 
bovine vaginal mucus, when colonies, consistent with C. fetus morphology, were subjected to 
conventional PCR, using MG3F/MG4R and VenSF/VenSR primers. Therefore, this method was 
chosen for testing vaginal mucus samples in the vaccine trial, described in the chapter 3. 
In the second study (Chapter 3) the pregnancy and infection rates between heifers, vaccinated 
with a polyvalent vaccine containing C. fetus antigen, and those, vaccinated with a comparable 
polyvalent product that did not contain C. fetus antigen heifers were compared. Heifers were 
paired by body weight and then randomized within each pair into treatment or control group. 
Animals of treatment and control groups expressed estrus and were adequately naturally 
challenged. There was no significant difference detected by treatment groups in the percentage of 
heifers that became infected with Cfv, the proportion of heifers that became pregnant, and the 
difference in days to pregnancy. However, serum concentration of C.fetus antibodies, detected by 
ELISA, was significantly higher in treatment group compare to control animals.  
Our visual heat detection and chin-ball markers results suggested that all heifers expressed estrus 
during the first 12 days and were mounted by bulls at least once by the day 17 of exposure. This 
was equally distributed between two treatment groups. There was also no difference by treatment 
in the time to expressing the first estrus and first bull mounting.  
In this study we used two bulls at the same time of exposure for 63 days. The bulls had 
satisfactory breeding soundness exams [21]. One of the bulls demonstrated significantly higher 
breeding activity, compare to another, in the first 12 days. When this more dominant bull was 
replaced due to a toe abscess, there was no difference in breeding activity between two 
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remaining bulls from days 13 to 21. However, every bull had similar breeding activity in both 
treatment groups during the study.         
The chin-ball marker results and high culture-positive rate for Cfv from vaginal mucus in both 
treatment groups suggest adequate challenge. One of the bulls was cultured positive for Cfv only 
once during the study, which might present a concern about adequate challenge of heifers. 
However, our chin-ball markers results demonstrated that all heifers that were mounted by that 
bull were also mounted by other bulls. Overall, 90% of heifers were mounted by more than one 
bull during the exposure. Those 10% of heifers, mounted by only one bull, were cultured positive 
several times during the study, also suggesting adequate challenge.  
When heifers, mounted by different bulls, were compared in the rate of cultured positive for Cfv 
at least once during the study, it was similarly high. Heifers were cultured same median number 
times positive for Cfv during the trial, no matter by which bull they were mounted. Pregnancy 
rate was low in both treatment groups, compare to be expected in beef heifers under the similar 
conditions, and was consistent with a reported natural BGC outbreak in western Canada [22].  
Overall, the infection challenge was achieved as a total of 86% of heifers, cultured positive for 
Cfv at least once during the study, and there was no significant difference between treatment 
groups. When this comparison was performed, the 95% confidence interval (CI) of odd ratio 
(OR) was of huge range, suggesting the possibility of issue with study power. However, all other 
95% CIs of ORs in this study were within less broad ranges. It would be smart though to increase 
sample size in future related studies.   
The highest proportion of vaginal mucus samples with Cfv isolated in our study occurred in 
weeks 4–6, which differed from weeks 7–15 in another similarly organized trial [22], most likely 
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because half of the animals in another study were additionally challenged at the day 39 of 
breeding season by an intravaginal instillation of Cfv [23]. Control groups of both studies 
demonstrated similar proportion of cultured positive in weeks 4–6.  
The uterine secretions are characterized by greater concentrations of IgG then IgA. In some 
animal models vaginal or nasal application of antigens resulted in optimal uterine response, but 
this has not been established for cattle [reviewed by 5].  
The efficacy of vaccination depends on adjuvants used. The majority of vaccines against C. fetus 
have been prepared with oil or aluminum hydroxide adjuvants [6, 7, 24, 25]. Alum was able to 
induce a good antibody response, but did not stimulate enough cellular immunity [26] and was 
not effective when administered, for example, orally or intra-nasally [27, 28]. Oil adjuvants 
stimulated strong antibody and cell-mediated responses but might cause an injection site 
granuloma [6, 7, 24]; however, newer oil containing adjuvants have been much improved [20, 
26]. For instance, monophosforyl lipid, isolated from lipopolysaccharide of Salmonella 
minnesota [29], acted on TLR4 and TLR2 [30], did not have inherent toxicity [29] and could be 
used on mucosal membranes [31].  
In our study, pregnancy rate was low and there was no significant difference between treatment 
groups. These results were in agreement with another study wherein heifers were vaccinated 
parentally on weeks 6 and 3 before breeding, with a polyvalent vaccine containing Cff and Cfv, 
and subsequently served by an infected bull for 60 days [25]. However, there was a different 
study, where the experimental vaccine in oleo adjuvant, containing local strains of T. foetus and 
C. fetus, yielded superior protection to the heifers exposed to infected bulls for 90 days [23].  
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When considering the pregnancy rates in our study, it is important to recognize that the heifers 
remained exposed to the bulls long enough to get pregnant, abort and become pregnant again. 
Half of heifers, pregnant at the end of the study, had aborted earlier. We cannot say whether our 
MAT titers showed improved immunity after abortion since a low number of titer-positives was 
detected by MAT throughout the study. However, the ELISA results allow to conclude that there 
was no significant difference in serum concentration of IgG to C. fetus between heifers that 
aborted during the study and those that not. Extending the length of bull exposure has likely 
improved the overall pregnancy rates in this study, but that might happen in a natural outbreak as 
well. The time to first detected pregnancy did not differ by treatment. Therefore, vaccination 
against BGC with polyvalent product did not significantly shorten time to conception  in our 
study.    
Most of the disagreements between ultrasound and serum PSPB were in the first weeks of the 
trial since early pregnancies could cause an increased PSPB concentration but be missed by 
ultrasound. PSPB has been reported to detect pregnancy about a week earlier than ultrasound 
[32, 33]. The PSPB level remains elevated for certain period of time after pregnancy loss; 
however, we used ultrasound to detect pregnancies a couple of weeks later, and only in two cows 
once elevated PSPB at the beginning wasn’t consequently confirmed by ultrasound. In addition, 
such error could be equally distributed in two groups. More than half of heifers in this study were 
never detected pregnant; whether they were actually never pregnant or just had early embryonic 
loss is questionable. It is often cited that Cfv results in pregnancy loss at 60–75 days [34, 35], but 
based on earlier methods of detection, losses could occur earlier. In our study about 90% of 
abortions happened before day 35 of gestation and abortion rate did not differ significantly by 
treatment.   
140 
 
Very few positive titers in serum samples from week 2 and 8 of exposure and 10 weeks after 
exposure were detected during our study, using the MAT method, suggesting no significant 
differences by week or treatment. After systemic immunization IgG and IgM antibodies are 
commonly detectable in serum, while IgA and IgG1 are transported across the epithelium into 
the genital secretions [36]. ELISA has been suggested as the best monitoring test for systemic 
antibodies against Campylobacter spp [37]. In our study significant rise in antibody titers were 
detected by ELISA in treatment group by week 4 after vaccination right before heifers were 
exposed to bulls. During the exposure period antibody titers value in the animals of treatment 
group were significantly higher than of control groups.  The commercial vaccine was able to 
induce antibody response in our study. However, even though the antigenic response in treatment 
groups was statistically higher, it was probably not as high as it could be when local antigen be 
used.    
The lack of significant antigenic response in our study could be due to antigenic difference 
between the local strain of the pathogen and that what was used in the commercial vaccine. In 
another study, a much higher rise in antibodies occurred after utilizing a local strain based 
vaccine than a commercial vaccine [38]. Alum generally induces an immunity of shorter duration 
than an oil adjuvant vaccine [38]. Using oleo adjuvant can induce significant antibody response, 
detectable by C. fetus-IgG ELISA test [23]. Therefore, it could be suggested that the adjuvant 
and/or antigen type of vaccine could cause poor antibody response in our study.     
4.2. FUTURE RESEARCH 
In our study some modifications were done to the existing heat lysis isolation protocol. All 
compared isolation methods had low sensitivity in relation to culture and one of possible 
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explanations is freeze-thaw process of the samples in our study. Rapid freezing results in 
intracellular ice crystal formation, whereas slow cooling allows water to leach out, reducing 
crystal formation but leading to osmotic pressure imbalance. Either rapid or slow cooling causes 
cell membranes to rupture. Ice crystal-induced damage to organelle structures leads to activation 
of rescue systems, associated with energy generation that results in production of free radicals 
and oxidative stress to DNA [reviewed by 39]. There are intracellular and extracellular 
cryoprotectants that can be added to samples. Intracellular agents prevent the formation of ice 
crystals and extracellular agents reduce the hyperosmotic effect during freezing [reviewed by 
39]. Therefore, further testing of the DNA isolation methods should be performed utilizing 
cryoprotectants or on fresh samples.  
The efficacy of vaccination depends on the antigen type and the adjuvant used. Antigenic 
difference between local and international strains may have caused the lack of vaccine 
effectiveness [40] and explained the significant rise of antibodies after utilizing the local strains 
in the vaccine [23] in one study, which was not the case in our study. Aluminum hydroxide 
adjuvants [6, 7, 24, 25] are able to induce a good antibody response but did not stimulate enough 
cellular immunity [26] and are not effective for mucosal vaccination [28]. Oil adjuvants 
stimulate strong antibody and cell-mediated responses but may cause an injection site granuloma 
[6, 7, 24]; however, newer oil containing adjuvants are much improved [20, 26]. It was suggested 
that alum generally induces an immunity of shorter duration than an oil adjuvant [38], and an 
oleo adjuvant can induce significant antibody response, detectable by a C. fetus-IgG ELISA test 
[23]. Therefore, future vaccine trials should be focused on the development and assessment of 
the vaccine, based on a local strain of Cfv antigen and a newer oil containing adjuvant.     
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4.3. GENERAL CONCLUSIONS 
The heat lysis isolation method, previously successfully utilized for bovine preputial samples, 
did not demonstrate satisfactory real-time PCR results for vaginal mucus. All compared sample 
preparation protocols were highly specific, but showed relatively low sensitivity; repeated 
sample freezing-thawing could be a possible reason. Heat lysis isolation of DNA directly from a 
CVM sample, skipping all dilution steps, is a simple technique that demonstrated relatively 
higher sensitivity than other compared heat lysis protocols.  The magnetic bead-based extraction 
protocol is tended to be even more sensitive, but time and resource consuming. Finally, these two 
methods should be further compared on fresh CVM samples. 
Vaccinating heifers with a polyvalent commercial vaccine, containing C. fetus antigen, according 
to the label did not significantly reduce infection rates or improve pregnancy when exposed to 
Cfv-infected bulls. Antigenic difference between local and international strains may have caused 
the lack of both significant immunogenic response and vaccine effectiveness. The most effective 
vaccines are prepared with oil adjuvants; they stimulate strong antibody and cell-mediated 
responses, and newer adjuvants of such types are much improved and do not cause side effects. 
Therefore, the vaccine, prepared with local Cfv strains and based on newer oil adjuvants should 
be created and evaluated.   
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